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GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation consists of a general introductory chapter that includes a short 
description of the research problem investigated by the author. The second chapter is a 
comprehensive review of the literature relevant to the research area explored by the author. 
The third, fourth, and fifth chapters are manuscripts published in the Journal of Nutrition that 
document research completed by the author of this dissertation that investigated the role of 
retinoids and glucocorticoids in the modulation of various aspects of folate and methyl group 
metabolism. The final chapter contains general conclusions regarding the significance of the 
research findings of the author as well as future directions that should be explored. 
Following the general conclusions chapter of this dissertation, a comprehensive list of 
references for the introduction, review of literature, and general conclusions is included. 
Each manuscript has its own list of references. 
Description of the Research Problem 
Folate, homocysteine, and methyl group metabolism are interrelated pathways 
collectively referred to as one-carbon metabolism that are important in health and disease. 
Through the interaction between these pathways, methyl groups supplied from dietary 
methionine or from the folate-dependent remethylation of homocysteine are activated to S-
adenosylmethionine (SAM), which then serves as a donor of methyl groups in a number of 
transmethylation reactions. SAM-dependent reactions are required for the synthesis and 
modification of numerous molecules, including polyamines, phosphatidylcholine, and 
neurotransmitters, as well as the methylation of DNA. Therefore, down regulation of one-
carbon metabolism may result in pathological consequences. Previous work in our 
laboratory demonstrated that the administration of the vitamin A derivative, 13-cz>retinoic 
acid produced conditions indicative of elevated methyl group catabolism (Schalinske and 
Steele 1991). Based in part on these findings, I hypothesized that the loss of methyl groups 
due to retinoid treatment was mediated by the inappropriate activation of glycine N-
methyltransferase (GNMT), a key cytosolic enzyme found primarily in the liver, kidney, and 
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pancreas that regulates the supply of SAM available for transmethylation reactions by 
disposing of excess methyl groups (Ogawa et al. 1998) and regulating the supply of methyl 
groups from the one-carbon pool (Wagner 1985). Moreover, I postulated that the loss of 
methyl groups through the activation of GNMT would lead to the down regulation of other 
SAM-dependent transmethylation reactions. 
In Chapter 3 of this dissertation, I showed for the first time that retinoids can up-
regulate hepatic GNMT activity and protein abundance in rats. To determine the 
physiological significance of these findings, I then conducted a series of experiments that 
examined the impact of GNMT up-regulation on other SAM-dependent transmethylation 
reactions. In Chapter 4,1 illustrated that retinoid-mediated induction of GNMT leads to the 
down-regulation of SAM-dependent methylation of hepatic DNA, suggesting that GNMT 
up-regulation can lead to conditions consistent with methyl group deficiency. 
GNMT activity has been shown to be elevated during uncontrolled diabetes (Xue and 
Snoswell 1985; Jacobs et al. 1998), a disease state associated with abnormal circulating 
concentrations of counter-regulatory hormones (i.e., glucagon and glucocorticoids) and 
increased expression of gluconeogenic enzymes. Furthermore, GNMT is found primarily in 
gluconeogenic tissues (e.g., liver, kidney, and pancreas) (Yeo and Wagner 1994). Therefore, 
I hypothesized that gluconeogenesis plays a critical role in regulating the expression of 
GNMT. In Chapter 5,1 demonstrated that, like retinoids, glucocorticoids possess the ability 
to increase the enzymatic activity and protein abundance of GNMT. In addition, I provide 
strong evidence that an interaction exists between retinoids and gluconeogenesis in the 
increased up-regulation of GNMT. Taken together, these findings implicate increased 
GNMT expression as a potential complication of diabetes and/or use of retinoids for 
therapeutic purposes. 
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REVIEW OF LITERATURE 
Folate Metabolism 
Biological Role of Folate Compounds 
Folate, otherwise known as pteroylmonoglutamate, is a generic term for a family of 
water soluble B-vitamins that function to accept and distribute one-carbon units to where 
they can be utilized in biosynthetic reactions that are required for maintenance of normal 
health. When its pteridine moeity is in its fully reduced form, folate becomes the 
physiologically functional molecule tetrahydrofolate (THF) (Figure 1). Within the cell, THF 
derivatives coexist in metabolic equilibrium in the cytosol and mitochondria, cellular 
compartments where folate-dependent one-carbon transfer reactions, collectively referred to 
as one-carbon metabolism, readily occur. Critical biological processes that require folate 
dependent one-carbon transfer reactions include the methylation of DNA and the synthesis of 
purines, pyrimidines, neurotransmitters, phospholipids, methionine, and polyamines. 
Therefore, aberrations of folate metabolism due to conditions such as folate deficiency and 
polymorphisms of folate-dependent enzymes have the ability to produce a number of 
pathological conditions. 
Absorption and Distribution of Folate Compounds 
Natural folate compounds are acquired from the diet mainly by consuming dark 
green, leafy vegetables and citrus fruits. Folate in its natural form consists primarily of 
polyglutamated molecules, which are hydrolyzed by y-glutamylhydrolase to the 
monoglutamated form in the gut prior to absorption across the intestinal mucosa (Shane 
1995). After its intestinal absorption, the monoglutamated folate molecule is bound by 
folate-binding proteins and then transported via portal circulation to the liver, where it is 
absorbed and metabolized to various polyglutamated derivatives, or released into the blood 
or bile primarily as 5-methyltetrahydrofolate (5-methyl-THF) (Shane 1995). After hepatic 
release of 5-methyl-THF into the blood, the folate derivative is bound by folate-binding 
proteins or albumins and transported to various tissues for use. Uptake of 5-methyl-THF into 
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Figure 1. Chemical structure of tetrabydrofolate and its various derivatives 
(reprinted from Molecular Genetics and Metabolism, Vol 71, Lucock, M., 
121-138, 2000, with permission from Elsevier). 
the cell is followed first by the removal of a methyl group by methionine synthase (MS) to 
generate THF, then the addition of several glutamate residues to the folate molecule by 
folylpolyglutamate synthase. This action serves to trap folate within the cell, where it is 
compartmentalized in the cytosol and mitochondria and readily converted to other folate 
derivatives. The addition of glutamate residues is also important for increasing the avidity of 
folate compounds for folate-dependent enzymes (Lucock 2000). Though trapped folate 
coenzymes and folate-dependent enzymes do not move freely between the two compartments 
within the cell, their metabolic products readily move between compartments as well as in 
and out of the cell (Bailey and Gregory 1999). 
The Folate-dependent One-carbon Pool 
Cellular folate coenzymes existing in metabolic equilibrium that have the ability to 
carry one-carbon units are collectively referred to as the folate-dependent one-carbon pool 
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(MacKenzie 1984). One-carbon units originating from the pool can undergo several redox 
reactions during folate metabolism (Figure 2). The oxidation-state of one-carbon units 
dictates both the position of the THF molecule to which they can bind as well as their 
biological function. Formate for example, binds to THF at the 10-position to form 10-
formyltetrahydrofolate (10-formyl-THF), which donates its one-carbon unit during the folate-
dependent de novo biosynthesis of the purine ring (Shane and Stokstad 1985). Conversely, 
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Figure 2. Folate-dependent one-carbon metabolism {reprinted from Molecular 
Genetics and Metabolism, Vol 71, Lucock, M., 121-138, 2000, with permission 
from Elsevier). 
a reduced derivative of formate, formaldehyde, binds to THF at both the 5- and 10-positions 
of THF to generate 5,10-methy lene-THF. 5,10-methylene-THF can then donate carbon units 
for three different purposes that include 1) the conversion of the pyrimidine uridylate to 
thymidylate by thymidylate synthase, a rate-limiting step in DNA synthesis, 2) reduction by 
5,10-methylenetetrahydrofolate reductase (MTHFR) to generate 5-methyl-THF, a folate 
coenzyme that is critical for the regulation of methyl group metabolism (Wagner et al. 1985) 
and the donation of methyl groups for the synthesis of methionine, or 3) oxidation by 5,10-
methylene-THF dehydrogenase to generate 5,10-methenyl-THF. 
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The following section describes the many other reactions that comprise folate-
dependent one-carbon metabolism in more detail and how one-carbon units enter the folate-
dependent one-carbon pool. 
Entrance of One-carbon Units Into the Folate-dependent One-carbon Pool 
There are five major folate-dependent one-carbon transfer reactions that occur in the 
mammalian cell: 1) conversion of serine to glycine, 2) catabolism of histidine, the synthesis 
of 3) thymidylate, 4) methionine, and 5) purine (Lucock 2000). Figure 2 illustrates the 
entrance of one-carbon units into the folate-dependent, one-carbon pool and the reactions that 
readily occur in the folate-dependent, one-carbon metabolism pathway. 
Amino acids are the primary source of one-carbon units that enter the folate-
dependent one-carbon pool with the major sources being serine and histidine (Wagner 1995). 
Serine enters the pool by transferring its formate group to THF to generate 5,10-methylene-
THF in a vitamin Independent reaction catalyzed by serine hydroxymethyltransferase 
(SHMT). The carbon unit from 5,10-methylene-THF is then used for the synthesis of 
thymidylate, oxidized to generate 5,10-methenyl-THF, or reduced to 5-methyl-THF. The 
methyl group from 5-methyl-THF is a particularly important substrate during methyl group 
metabolism because it is used for the remethylation of homocysteine in a B ^ -dependent 
reaction catalyzed by methionine synthase (MS) to generate methionine, which serves as a 
major source of methyl groups in transmethylation reactions. Histidine, another amino acid, 
donates one-carbon units to the folate-dependent one-carbon pool that are generated from its 
catabolism. The histidine breakdown product formiminoglutamate enters the pool by binding 
to THF at the 5-position to form 5-formyltetrahydrofolate (5-formyl-THF), which can be 
reduced to 5,10-methenyl-THF by 5,10-methenyl-THF reductase. 
In addition to being donated by serine, formate can enter directly into the one-carbon 
pool as formic acid through a reaction catalyzed by 10-formyl-THF synthase, which attaches 
formic acid to THF at the lO-position, generating 10-formyl-THF in the process. The carbon 
group from 10-formyl-THF is used as a substrate during the synthesis of purines in reactions 
catalyzed by glycinamide ribonucleotide (GAR) transformylase and 5-amino-4-imidazole 
carboxamide ribonucleotide (AICAR) transformylase, respectively, or readily converted to 
5,10-methenyl-THF in a reversible reaction catalyzed by methenyl-THF cyclohydrolase. 
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During conditions where adequate one-carbon units are available in the one-carbon pool, the 
formate group of 10-formyl-THF is disposed of as CO2, in a reaction catalyzed by 10-formyl-
THF dehydrogenase (Kutzbach and Stokstad 1968). 
Clearly, the interrelated pathways of one-carbon metabolism are extremely complex 
and require a number of substrates and enzymes to function properly. The importance of 
these pathways with respect to methyl group metabolism will be focused on in greater detail 
below and will be one of the focal points of this thesis. 
Methyl Group Metabolism 
General Overview of Methyl Group Metabolism 
Methyl group metabolism refers to a group of tightly coordinated reactions that 
supply methyl groups for use in over 100 transmethylation reactions. Enzymes involved in 
methyl group metabolism are found in most organs, but all are prevalent in the liver, where 
the majority of methyl group metabolism regulation is believed to occur (Finkelstein 1990). 
Methionine, which is synthesized de novo or provided from the diet, serves as the source of 
methyl groups for transmethylation reactions. In a reaction catalyzed by methionine 
adenosyltransferase (MAT), an adenosine molecule is attached to methionine to generate 
SAM, thereby activating methyl groups for use in transmethylation reactions (Figure 3) 
(Cantoni 1982; Cantoni and Chiang 1980; Mudd 1963). SAM-dependent transmethylation 
reactions, approximately 85% of which are believed to occur in the liver (Mato et al. 1994), 
are required for the biosynthesis of macromolecules such as phospholipids, 
neurotransmitters, and polyamines, as well as for the methylation of proteins and nucleic 
acids (Cantoni 1982; Cantoni and Chiang 1980). Therefore, acquiring an adequate dietary 
supply of methyl groups is a critical aspect of maintaining optimal health. 
Following its donation of a methyl group for SAM-dependent transmethylation reactions, 
SAM is converted to S-adenosylhomocysteine (SAH), which is catabolized to generate 
homocysteine and adenosine by SAH hydrolase. The formation of homocysteine represents 
a metabolic branch point in the pathway because homocysteine is either remethylated to 
regenerate methionine or committed to the transsudation pathway for its catabolism. 
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Figure 3. Methyl group metabolism. 
During the remethylation process, methyl groups are utilized to remethylate homocysteine 
and generate methionine de novo by one of two methods: 1) addition of a methyl group from 
5-methyl-THF to homocysteine in a vitamin Bn-dependent reaction catalyzed by MS or 2) 
the addition of a methyl group by the choline derivative, betaine by betaine homocysteine 
methyltransferase (BHMT). Finkelstein and Martin (1984) reported that MS and BHMT, the 
latter being found primarily in the liver and kidney (Ueland and Refsum 1989), are equally 
important for the remethylation of homocysteine. The remethylation process ensures that the 
carbon chain of methionine is recycled for use in SAM-dependent transmethylation reactions 
multiple times (Eloranta et al. 1990). 
If homocysteine is not remethylated, it is committed to the transsulfuration pathway 
by cystathionine ^-synthase (C(5S) for its catabolism in a vitamin Be-dependent reaction that 
condenses homocysteine with serine to generate cystathionine (Finkelstein and Chalmers 
1970), a molecule that is required for the synthesis of the essential compounds cysteine and 
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glutathione. The removal of homocysteine through transsulfuration by CPS is critical for 
maintaining normal methyl group metabolism; this is because the conversion of 
homocysteine back to SAH is kinetically favored (Cantoni and Chiang 1980), and SAH 
inhibits not only transmethylation reactions (Kerr 1972), but also the remethylation of 
homocysteine (Finkelstein et al. 1974). 
Regulation of Methyl Group Metabolism 
Allosteric regulation 
The methyl group- and folate-dependent one-carbon metabolism pathways interact 
with each other to ensure an adequate supply of methyl groups is available for 
transmethylation reactions. In order to optimize the supply of methyl groups, a number of 
regulatory mechanisms exist between the two pathways that serve to normalize the methyl 
group supply when it fluctuates (Figure 4). During conditions of elevated intracellular 
methionine concentrations for example, an increase in the supply of SAM occurs (Henning 
Dimethylglycine THF 
-SAM BE 
Retain 
GNMT—fn MS 
• ... 1 sarcosine 
[omocysteine— g 
CPS|+SAM, glucagon, glucocorticoids 
I — insulin 
*MTH] 
5-methyl-THF 
5,10-methylene-THF 
Other THF 
coenzymes 
— insulin 
5 
Cystathionine 
Figure 4. Regulation of methyl group metabolism. 
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et al. 1989). The elevation of SAM concentrations produces numerous regulatory 
consequences because SAM acts as an allosteric effector of several enzymes that catalyze 
critical methyl group- and folate-dependent reactions. The modulation of enzymes in the 
pathway during conditions of increased SAM levels serves two important purposes that 
include, 1) the inhibition of the flow of unneeded methyl groups into the pathway from both 
de novo sources, betaine (Finkelstein and Martin 1984) and the folate-dependent one-carbon 
pool (Kutzbach and Stokstad 1971) and 2) the normalization of the supply of SAM by 
facilitating its catabolism (Ogawa and Fujioka 1982). The SAM-mediated inhibition of both 
BHMT activity (Finkelstein and Martin 1984) and the conversion of 5,10-methylene-THF to 
5-methyl-THF by MTHFR (Kutzbach and Stokstad 1967; 1971) diverts one-carbon units to 
where they can serve other important functions when there is an adequate supply of 
intracellular SAM for transmethylation reactions. With decreased 5-methyl-THF 
concentrations due to SAM-mediated inhibition of MTHFR, significant changes occur 
elsewhere in the methyl group metabolism pathway because 5-methyl-THF is an inhibitory 
ligand for glycine ^-methyltransferase (GNMT) (Wagner et al. 1985), a key cytosolic protein 
that regulates the SAM/SAH ratio by disposing of excess SAM as sarcosine (Kerr 1972), a 
molecule with no known metabolic function. Therefore, when cellular 5-methyl-THF levels 
are decreased, GNMT becomes more active (Balaghi et al. 1993) and serves to normalize 
SAM concentrations and the SAM/SAH ratio by facilitating the catabolism of SAM. The 
regulation of the SAM/SAH ratio by GNMT is critical because this ratio is considered an 
index of transmethylation potential due to the ability of SAH to be a potent inhibitor of most 
methyltransferases (Kerr 1972). Elevated SAM concentrations also allosterically activate 
CPS (Finkelstein and Martin 1986), which assists in the catabolism of SAM by committing 
the increased volume of SAM degradation products to the transsulfuration pathway, as 
previously described. 
Under conditions where SAM levels are decreased, highly coordinated mechanisms 
are in place to restore them. A decrease in SAM concentration releases MTHFR inhibition 
(Kutzbach and Stokstad 1967), which then facilitates the increased production of 5-methyl-
THF. Consequently, the folate-dependent remethylation of homocysteine and subsequent 
flow of methyl groups from the one-carbon pool into the methyl group metabolism pathway 
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for production of SAM increase. The rise in 5-methyl-THF concentrations also allosterically 
inhibits GNMT activity, which serves to slow the disposal of SAM in order to conserve it for 
other transmethylation reactions (Wagner et al. 1985). Additionally, BHMT inhibition is 
released as SAM concentrations decline (Finkelstein and Martin 1984), which can then aid in 
the regeneration of methionine through the remethylation of homocysteine. 
Hormonal modulation of methyl group metabolism 
Several hormones are known to regulate the expression of key enzymes involved in 
methyl group metabolism. Hormones known to modulate methyl group metabolism include 
glucagon, glucocorticoids, insulin, thyroxine (thyroid hormone), and growth hormone. 
Although many of the general mechanisms by which these hormones exert their actions are 
known, the physiological consequences of their actions with respect to methyl group 
metabolism are poorly understood. Recent evidence suggests that the modulation of methyl 
group metabolism by hormones occurs as a result of alterations of glucose metabolism 
(Jacobs et al. 1998; 2001 ; Ratnam et al. 2002; Xue and Snoswell 1985). 
Glucagon, glucocorticoids, and insulin. Hormones secreted at increased rates 
during a catabolic state (i.e. gluconeogenesis) such as glucagon and glucocorticoids (i.e. 
counter-regulatory hormones), appear to enhance the catabolism of methionine (Gil et al. 
1997; Jacobs et al. 1998; 2001; Ratnam et al. 2002). In tissue culture and rat studies, 
treatment with glucocorticoids hormones elevated the gene expression of MAT 3-fold (Gil et 
al. 1997), whereas glucocorticoid (Ratnam et al 2002) and glucagon (Jacobs et al. 2001) 
treatment increased CPS gene expression 1.5- and 2-fold, respectively. In all the described 
cases, treatment with insulin was effective in blocking the hormone-mediated induction of 
these enzymes. Additionally, CPS expression was elevated in streptozotocin-diabetic rats, 
animals that exhibit conditions consistent with elevated levels of counter-regulatory 
hormones, whereas insulin treatment was effective in preventing this occurrence (Ratnam et 
al. 2002). These findings suggest that the physiological consequences of up-regulated 
methionine metabolism may have significance during uncontrolled diabetes, during which 
insulin utilization is compromised and an increased circulating concentration of counter-
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regulatory hormones is unchecked. Because methionine serves as an important source of 
methyl groups, its increased catabolism could have a detrimental effect on SAM-dependent 
transmethylation reactions. Xue and Snoswell (1985) found that the disposal of methyl 
groups by GNMT was increased 65-fold in alloxan-diabetic sheep, suggesting that diabetic 
conditions do in fact lead to unwarranted loss of methyl groups; however, it has yet to be 
investigated whether the increased disposal of methyl groups GNMT compromises other 
SAM-dependent transmethylation reactions. 
Growth hormone and thyroxine. Associations between both thyroid (thyroxine) 
and growth hormones and the modulation of methyl group metabolism clearly exist, but are 
not well understood and contradictory. In animal studies, it appears that both hormones play 
an inhibitory role in the catabolism of methionine and its products, whereas the opposite 
effect usually occurs in humans. Animal experiments have demonstrated that the expression 
GNMT mRNA is decreased in growth hormone-treated mice (Aida et al. 1997). Moreover, 
Ames dwarf mice, animals that are deficient in growth hormone, prolactin, and thyroid 
stimulating hormone, exhibited symptoms consistent with elevated methionine catabolism 
including, increased activities of MAT (203%), CPS (50%), cystathionine y-lyase (83%), and 
GNMT (91%) (Uthus and Brown-Borg 2003). Similarly, hypothyroid rats have been shown 
to exhibit decreased plasma homocysteine levels, which appear to be normalized by 
treatment with thyroxine (Jacobs et al. 2000). Collectively, these reports clearly indicate that 
thyroid and growth hormones play an integral role in modulating methionine metabolism, 
although that role is unclear. Interestingly, thyroxine administration to rats has been shown 
to increase the activity of hepatic BHMT (Finkelstein et al. 1971), demonstrating that in 
addition to modulating the activity of enzymes involved in the transsulfuration pathway, 
thyroxine may modulate homocysteine levels through its effect on the remethylation 
pathway. 
In contrast to animal studies, human studies have demonstrated that growth hormone 
deficiency and hypothyroidism are conditions that appear to inhibit homocysteine catabolism 
(Sesmilo et al. 2001). Hussein et al. (1999) found that individuals suffering from 
hypothyroidism exhibited hyperhomocysteinemia, which was normalized by treatment with 
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thyroxine. Similarly, treatment with growth hormone has been shown to reduce elevated 
plasma homocysteine levels in patients with growth hormone deficiency (Sesmilo et al. 
2001). Because these findings contradict those from animal studies, it appears that animal 
models are not a useful tool for studying the role of growth hormone and thyroxine in the 
modulation of methyl group metabolism in humans. 
Dietary Requirements 
Folate Requirements 
Dietary Reference Intakes 
In 2000, the latest dietary reference intakes (DRIs) reported by the Food and Nutrition 
Board based folate recommendations on data that was collected from controlled metabolic 
studies where blood folate concentrations were measured, and from data collected in 
population-based studies [Food and Nutrition Board (FNB) 2000]. DRI values for folate are 
expressed as dietary folate equivalents (DFE), where 1 DFE = 1 p,g food folate = 0.6 (ig of 
folic acid from fortified food or as a supplement consumed with food = 0.5 jug of a folic acid 
supplement taken on an empty stomach (FNB 2000). Folic acid refers to the synthetic 
derivative of folate, which has been shown to be more bioavailable than naturally occurring 
food folate, presumably due to the greater instability of food folate (O'Broin, et al 1975). 
Folate DRIs include a recommended daily allowance (RDA) that advises a minimum daily 
intake DFE for all age groups [except for infants (0-12 months)], including pregnant and/or 
lactating adults. Regardless of gender, once individuals reach age 14 years old, the RDA (400 
DFE per day) remains constant in males and non-pregnant females. For pregnant and 
lactating adults, the RDA for folate is 600 and 500 DFE, respectively. Infants' daily 
requirements are expressed as adequate intakes (AI), which equals the DFE of folate an 
infant must consume daily in order to meet the requirements of the individuals in a particular 
infant age group. For infants 0-6 months of age, the AI of folate is 65 DFE, which increases 
to 80 DFE as infants reach the 7-12-month age group (FNB 2000). In addition to RDA and 
AI values, the DRIs for folate include an upper limit (UL), which is defined as the maximal 
daily nutrient intake that is likely to pose no risk of adverse effects (FNB 2000). In the case 
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of folate, an UL is listed because excessive consumption can mask symptoms of vitamin Bi2 
(i.e. cobalamin) deficiency while neurological damage due to vitamin B12 deficiency is 
allowed to progress undetected (FNB 2000). With pregnancy and lactation being exceptions, 
the RDA and UL for folate increases with age (300-800 DFE) then becomes stable (1000 
DFE) when individuals reach 19 years of age. 
Folate requirements during pregnancy 
A strong correlation between low folate status and an elevated incidence of neural 
tube defects (NTDs) has been well documented (Mulinare et al. 1988; Werler et al. 1993; 
Milunsky et al. 1989). Vital biological processes that occur during fetal development 
requiring folate-dependent reactions include cell division, neural tube closure of the 
developing fetus during pregnancy, and a number of reactions requiring methyl groups. Out 
of an estimated 4000 pregnancies in the U.S. that are affected with NTDs each year, it is 
currently believed that 50% or more can be prevented by consuming a folic acid-containing 
supplement before and during the early weeks of pregnancy in addition to meeting dietary 
folate requirements [American Academy of Pediatrics (AAP) Committee on Genetics 1999]. 
In order to decrease the incidence of NTDs in women who have no history of a previous 
NTD-affected pregnancy as well as those women who have had a child with a NTD, new 
recommendations for folate consumption were developed by the US Public Health Service 
(USPHS) and Centers for Disease Control and Prevention (CDC) (CDC 1991; 1992). The 
USPHS recommendation for folate intake by women with no prior NTD-affected pregnancy 
who are of childbearing age is 400 pg of folic acid per day in addition to the dietary 
requirement (RDA) of400 DFE from food (CDC 1991; 1992). These recommendations have 
been endorsed by the AAP (AAP Committee on Genetics 1999). For those women who have 
had NTD-affected pregnancies, the recommendation is a 4000 ng daily dosage of folic acid, 
which should not be consumed through the taking of over-the-counter folic acid-containing 
prescription multivitamins due to toxicity issues involving other nutrients (CDC 1991; 1992). 
The AAP recommended that these women should be offered prophylaxis (4000 |ig DFE) one 
month before the time they plan to become pregnant and throughout the first 3 months of 
pregnancy (AAP Committee on Genetics 1999). However, these new recommendations may 
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reflect a need to review and perhaps redesign the current DRIs for pregnancy because the 
requirements endorsed by the AAP obviously differ from the current RDA of 600 DFE per 
day. 
Methyl Group Requirements 
Methyl groups that are utilized for SAM-dependent transmethylation reactions 
originate from the folate-dependent one-carbon pool or from essentially two dietary sources, 
methionine and choline. Methionine, an abundant essential amino acid in protein, is very 
toxic if consumed excessively (Benevenga and Steele 1984) and no dietary recommendations 
are currently in place for its consumption. However, as with all of the other essential amino 
acids, it is a reasonable assumption that daily protein requirements should be met to ensure 
that an adequate supply of methionine is consumed. An AI for choline is included in the 
current DRIs, although there are few data to assess whether a dietary supply is needed at all 
stages of the life cycle (FNB 2000). The AI for choline is 125-150 mg/day for infants and 
increases throughout childhood (200-250 mg/day) into adulthood, where the requirement is 
greater for males than for females (FNB 2000). According to the latest DRIs, the AI for 
adult males is 550 mg/day, whereas three separate AI classifications for female requirements 
exist. These classification groups include women that are non-pregnant and non-lactating, 
pregnant, or lactating (FNB 2000). The adult AI for non-lactating, non-pregnant women is 
425 mg/day (FNB 2000). During pregnancy the AI is increased to 450 mg/day, whereas 
lactation increases the requirement to 550 mg/day (FNB 2000). 
One-Carbon Metabolism in Health and Disease 
General Overview 
Diseases related to folate and/or methyl group deficiency can be catastrophic. As 
discussed previously, methyl group- and folate-dependent one-carbon metabolism are 
interrelated pathways that involve a large number of enzymes and metabolites that play 
major roles in sustaining life processes. The synthesis of nucleic acids, phospholipids, 
neurotransmitters, and polyamines, along with functions such as the methylation of DNA and 
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neural tube closure in the fetus, all require folate and methyl groups in some capacity. In 
addition to a lack of folate and sources of methyl groups in the diet, deficiencies of vitamin 
B12 or vitamin B&, a number of drugs, such as anticonvulsants, oral contraceptives, retinoid-
containing acne medications, and numerous environmental toxins can all perturb one-carbon 
metabolism reactions. Moreover, several genetic polymorphisms of enzymes and metabolic 
diseases, such as diabetes mellitus, have been implicated as factors that have a major impact 
on folate and/or methyl group requirements. 
Neural Tube Defects 
The role of folate and methyl group metabolism during fetal development is 
important for developing dietary recommendations for the prevention of birth defects, 
namely NTDs (Coelho et al. 1989; Coelho and Klein 1990; Lau and Li 1995; Kirke et al. 
1993). NTDs, caused by congenital defects such as spina bifida, anencephalus 
(approximately 50% and 40% of cases, respectively), encephalocele, and iniencephaly (Scott 
et al. 1990), make up approximately 1 of 1000 births in the United States (AAP Committee 
on Genetics 1999) and are influenced by a number of nutritional factors, especially folate-
and methyl group metabolism. Poor nutrition can lead to the perturbation of one-carbon 
metabolism, which, in turn, may lead to the inhibition of essential processes required for fetal 
development such as DNA synthesis and methylation, polyamine and phospholipid synthesis, 
and the post-translational modification of myelin basic protein, a protein required for neural 
tube closure (Benjamins et al. 1984; Chiang, et al. 1996). 
The identification of folate as a dietary factor that clearly influences the outcome of 
pregnancies has been known for over 50 years. In 1949, it was first observed that rats kept 
on diets deficient in folic acid prior to gestation exhibited 100% resorption of their fetuses 
(Nelson and Evans 1949). Soon after, similar findings were reported in human studies, 
where spontaneous abortions occurred in individuals that unknowingly consumed folic acid 
antagonists prior to gestation (Thiersch 1952; Goetsch 1962). Findings such as these have 
helped spark intense research to determine the importance of folic acid supplementation 
during pregnancy. Data collected from case-control (Mulinare et al. 1988; Werler et al. 1993) 
and prospective (Milunsky et al. 1989) studies have provided strong evidence that folic acid 
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supplementation during periconception, a six-month period including three months prior 
through three months after conception, results in a significant decline in the incidence of 
NTD-affected pregnancies. These findings contributed to the 1992 decision of the USPHS to 
recommend that all reproductive-aged women capable of becoming pregnant should consume 
a daily dose of 400 jig of folic acid (CDC 1992) in addition to DFE consumed in the diet. 
However, this recommendation proved to be a failure. In fact, by 1998 only 29% of women 
in the United States were following the USPHS recommendation for folic acid consumption 
(CDC 1999). As a result, the United States Food and Drug Administration (USFDA) 
authorized mandatory folic acid fortification of grain products in the United States effective 
1998, which is believed to have led to a 19% reduction in the incidence of NTDs (Honein et 
al. 2001). 
Although the association between folate deficiency and alterations of embryogenesis 
is almost indisputable, the mechanistic link between folate deficiency and the increased 
incidence of NTDs is a topic of ongoing debate. It is well established that folate-dependent 
reactions are required for the synthesis ofDNA and cell division during fetal development; 
however, current evidence suggests that abnormalities of other aspects of one-carbon 
metabolism associated with folate deficiency, such as hyperhomocysteinemia (Steegers-
Theunissen 1994), play a significant role in the etiology of NTDs. Because folate is required 
for maintaining normal homocysteine concentrations (Brattstrom et al. 1988), it is possible 
that folate supplementation reduces the incidence of NTDs through its role in the 
remethylation pathway. Interestingly, a deficiency of vitamin Bi2, a nutrient also required for 
the remethylation of homocysteine, has been implicated as an independent risk factor for 
NTDs (Daly et al. 1995). Additionally, genetic polymorphisms that produce deficiencies of 
C|3S and MTHFR, enzymes that play central roles in homocysteine metabolism, have been 
strongly associated with an increased incidence of NTDs (Engbersen et al. 1995; Mills et al. 
1995; Christensen et al. 1999). Thus, monitoring plasma homocysteine and screening for 
genetic polymorphisms during pregnancy may be useful strategies for decreasing the 
incidence of NTDs in addition to dietary intervention with folic acid (Brattstrom et al. 1988), 
vitamin Bn (Kirke et al. 1993), and vitamin B& supplementation (Cuskelly et al. 2001). 
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The inverse relationship between plasma homocysteine levels and the incidence of 
NTDs may also be related to the maintenance of normal methionine concentrations by folate-
dependent remethylation (Eskes 1998). In vitro studies using embryo cultures and in vivo 
models have demonstrated that methionine is essential for neural tube closure (Coelho et al. 
1989; Essien and Wannberg 1993). Likewise, additional methionine in the diet has been 
shown to decrease the incidence of NTDs in mice administered retinoid compounds (Lau and 
Li 1995), which are known to be teratogenic with respect to fetal development (Lammer et 
al. 1985) perhaps because of their ability to enhance the catabolism of methionine (Peng and 
Evenson 1982; Schalinske and Steele 1991) and alter the distribution of folate coenzymes in 
the folate-dependent one-carbon pool (Fell and Steele 1986). As discussed previously, 
methyl groups provided by methionine and the folate-dependent one-carbon pool are 
activated to SAM for use in transmethylation reactions, many of which are required during 
fetal development, including polyamine and phospholipid synthesis (Chiang et al. 1996), as 
well as the post-translational modification of myelin basic protein (Benjamins et al. 1984; 
Chiang et al. 1996). Because adequate folate status is essential for the maintenance of 
normal SAM concentrations (Balaghi et al. 1993), a lack of folate coenzymes that are 
capable of transferring methyl groups during the de novo synthesis of SAM may therefore be 
responsible, at least in part, for the increased incidence of NTDs due to folate and folate-
dependent enzyme deficiencies. 
Hyperhomocysteinemia and Cardiovascular Disease 
Hyperhomocysteinemia as a risk factor for cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of mortality in the United States 
according to the latest report by the CDC using data collected from 2001 (United States 
Department of Health and Human Services 2003). Hyperhomocysteinemia has recently been 
added to the list of other commonly known risk factors for CVD such as hypertension, 
elevated low-density lipoprotein (LDL) concentrations, and smoking (Clarke et al. 1991). 
Research that led to the identification of hyperhomocysteinemia as a risk factor for CVD 
began over 30 years ago when homocysteine was in question as a possible underlying factor 
in the development of vascular lesions in an infant with abnormal vitamin Bn metabolism 
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and homocystinuria (McCully 1969). Since then, growing evidence has strongly associated 
hyperhomocysteinemia with vascular lesions and premature development of CVD (McCully 
and Wilson 1975; Brattstrom et al. 1992; Kang et al. 1986; Clarke et al. 1991). In 1991, 
Clarke et al. (1991) examined patients who were diagnosed with vascular disease before age 
55 and found that homocysteine levels were 33% higher in those with vascular disease than 
in control subjects following a standard methionine-loading test. 
Strong evidence exists that implicates homocysteine as an atherogenic compound. 
For example, direct administration of homocysteine thiolactone produces severe 
arteriosclerosis in rabbits (McCully and Ragsdale 1970), but the exact mechanism by which 
the molecule causes vascular dysfunction is not known. In a recent review, Haynes (2003) 
concluded that increased plasma homocysteine levels have the potential to mediate several 
atherogenic effects, including increased oxidative stress, impaired endothelial function, 
stimulation of mitogenesis, and induction of thrombosis. 
Regulation of homocysteine metabolism 
In order to maintain normal concentrations of plasma homocysteine, a highly 
coordinated system for homocysteine removal is in place. As previously mentioned, 
homocysteine is metabolized via three separate reactions: 1) vitamin Bg-dependent 
conversion of homocysteine to cystathionine by CpS followed by catabolism through the 
transsudation pathway, 2) folate- and vitamin B^-dependent remethylation by MS, and 3) 
betaine-dependent remethylation by BHMT, a reaction confined primarily to the liver and 
kidney (Finkelstein 1990). It has been reported that under normal conditions, approximately 
46% of homocysteine is committed to the transsudation pathway by CPS, with the rest 
being remethylated by MS and BHMT (approximately 27% and 27%, respectively) 
(Finkelstein and Martin 1984). A recent study demonstrated that homocysteine levels are also 
inversely related to the activity of phosphatidylethanolamine M-methyltransferase (Noga, et 
al. 2003), an enzyme responsible for the conversion of phosphatidylethanolamine to 
phosphatidylcholine, a source of choline that can serve as a source of three methyl groups for 
the betaine-dependent remethylation of homocysteine via BHMT. 
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Although CPS is responsible for removing the majority of circulating homocysteine 
compared to MS and BHMT, coordination between all three of these enzymes is crucial for 
the maintenance of normal homocysteine metabolism. In certain cases, a deficiency of one of 
the enzymes needed for the removal of homocysteine results in homocysteinemia, indicating 
that all three must function optimally to maintain normal homocysteine levels and 
compensation needed for the removal of excess homocysteine by complementary enzymes is 
limited. 
Enzyme deficiencies due to polymorphisms of CPS and MTHFR, as well as 
nutritional deficiencies or defects in the transport of folate, vitamin Be (i.e. pyridoxal 
phosphate), and/or vitamin B12, drugs, and metabolic diseases are among the conditions that 
have been associated with elevated homocysteine concentrations (Green and Jacobsen 1995). 
Deficiencies of folate, vitamin Be (i.e. pyridoxal phosphate), and/or vitamin B12 can also 
exacerbate abnormal methyl group metabolism caused by preexisting genetic conditions 
(Kluitmans et al. 2003). Taken together, the complexity of coordinating the activity of a 
number of enzymes and maintaining adequate nutritional status imparts a large number of 
potential causes for perturbation of homocysteine metabolism. In the following section, the 
causes and treatments of hyperhomocysteinemia with respect to metabolic disorders and 
nutrition will be reviewed in greater detail. 
Etiology of Hyperhomocysteinemia 
Enzyme deficiencies 
Cystathionine (3-synthase (CPS) polymorphisms. As discussed previously, CpS 
catalyzes the condensation of homocysteine and serine in a vitamin Be-dependent reaction 
that produces cystathionine, committing homocysteine to the transsulfuration pathway for its 
catabolism in the process. A deficiency of CpS, usually caused by a 68-bp insertion between 
nucleotide 844 and 845 of the CpS gene (Sebastio et al. 1995), is the most common inborn 
error of methionine metabolism, occurring in 1 in 200,000 of the general population 
worldwide (Selhub and Miller 1992). This particular CpS mutation has been called a 
"classical congenital disorder" because it is inherited as an autosomal recessive trait 
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(Kluitjmans et al. 1999) and results in the blocking of the transsulfuration pathway 
(Finkelstein et al. 1964). 
The importance of CpS during the removal of excess homocysteine has been 
examined by Finkelstein and Martin (1984), who demonstrated in vitro that compared to 
BHMT and MS, CpS plays a much larger role in the removal of homocysteine when the flux 
through the methyl group metabolism pathway is increased. Therefore, it is not surprising 
that individuals with CpS deficiency are at an increased risk for developing severe 
hyperhomocysteinemia (Boddie et al. 1998; Silaste et al. 2001), cardiovascular disease 
(Ueland and Refsum 1989), and vascular dysfunction (Lentz et al. 2000). Likewise, 
individuals with CpS deficiency are more likely to suffer from other conditions that are 
consistent with hyperhomocysteinemia including, skeletal anomalies, mental retardation, and 
dislocation of the optic lens (Ueland and Refsum 1989). 
Complications associated with CPS deficiency are exacerbated when combined with 
folate deficiency (Lentz 2000), a condition that simultaneously down-regulates the 
remethylation system and contributes to elevated plasma homocysteine concentrations (Jacob 
et al. 1994; Cuskelly et al. 2001). Folate deficiency may also contribute to homocysteinemia 
during CPS deficiency by indirectly leading to the enhanced catabolism of dietary 
methionine. A decline in the supply of 5-methyl-THF releases its inhibition of GNMT and as 
a result, increases the catabolism of SAM (Wagner et al. 1985). With the resulting elevation 
of GNMT activity, an increased production of methionine degradation products occurs and 
homocysteine levels are allowed to build up uncontrollably because defective CPS cannot 
commit homocysteine to the transsulfuration pathway and folate is unavailable for its 
remethylation (Selhub 1999). Similarly, when there is an adequate supply of folate, CpS 
deficiency still can cause hyperhomocysteinemia, but folate-dependent remethylation helps 
alleviate the buildup of homocysteine due to CpS deficiency because homocysteine can be 
diverted toward the remethylation pathway when homocysteine concentrations build up 
(Selhub 1999). However, the diversion of homocysteine toward the folate-dependent 
remethylation pathway during CpS deficiency is only transient. With CPS deficiency, the 
inhibition of the transsulfuration pathway leads to increased SAM concentrations (Selhub 
1999). As SAM concentrations reach the level where it is able to cause feedback inhibition 
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of MTHFR, inhibition of the remethylation system occurs and hyperhomocysteinemia is the 
end result. 
Methylenetetrahydrofolate reductase (MTHFR) polymorphisms. Hyperhomo­
cysteinemia has been implicated as the underlying cause of extensive abnormalities in the 
arterial bed (Harmon et al. 1996), vascular thrombosis (Kanwar et al. 1976), and coronary 
artery disease (Kang et al. 1988) in cardiovascular patients carrying a mutation of the 
MTHFR gene. The two most common mutations of the MTHFR gene include base pair 
substitutions at either bp 677, which is associated with hyperhomocysteinemia (Goyette et al. 
1995), or bp 1298, which apparently has little or no influence on homocysteine 
concentrations (Friedman, et al. 1999). The mutation of the MTHFR gene at bp 677 resulting 
from a C->T substitution (C677T) is commonly referred to as "thermolabile" MTHFR, due 
to its instability at increased temperatures. Like Cj3S deficiency, the C677T mutation of 
MTHFR is autosomal recessive and has been associated with homocysteinemia (Engbersen, 
et al. 1995) and cardiovascular disease (Kang, et al. 1988; Engbersen, et al. 1995) in 
individuals with the homozygotic genotype. The C6777T mutation of MTHFR is more 
prevalent than C(3S deficiency however, with the homozygotic genotype (T/T) occurring in 
-12% of caucasian and asian populations (Brattstrom et al. 1988; Frosst et al. 1995). 
Individuals carrying the homozygotic genotype appear to be more prone to elevated 
homocysteine levels than individuals carrying the heterozygotic (C/T) genotype for the 
C677T mutation (Silaste et al. 2001; Kluijtmans et al. 2003). 
Unlike CpS deficiency where the cause of homocysteinemia has been established, the 
mechanism by which MTHFR deficiency causes hyperhomocysteinemia is not well 
understood. Recent evidence suggests that low folate status in combination with MTHFR 
deficiency leads to hyperhomocysteinemia (Bostom, et al. 1996; Meleady, et al. 2003). 
Likewise, researchers have discovered that individuals with the T/T mutation are more likely 
to exhibit significantly lower baseline plasma and red cell folate levels than individuals 
carrying the T/C or C/C genotypes (Kluijtmans et al. 2003; Meleady, et al. 2003). 
Furthermore, Nelen et al. (1998) and Silaste et al. (2001) found that folate supplementation 
was not as effective in improving folate status in T/T individuals when compared to the T/C 
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and C/C genotypes, but was effective in normalizing their homocysteine concentrations. 
These findings suggest that individuals suffering from MTHFR deficiency may need to 
consume supplemental folate in order to maintain adequate MTHFR activity. In a recent 
review, Bailey and Gregory (1999) proposed that when folate status is adequate, normal 
plasma homocysteine levels should be maintained, independent of genotype. Therefore, 
individuals with thermolabile MTHFR may require folate supplementation in order to 1) 
supply 5-methyl-THF for remethylation of homocysteine by bypassing the MTHFR reaction 
and/or 2) to provide excess folate substrates to ensure that a dysfunctional MTHFR enzyme 
is able to produce an adequate supply of 5-methyl-THF. 
Methionine synthase (MS) and betaine:homocysteine methyltransferase (BHMT) 
polymorphisms. Recent studies that have examined the correlation between MS and 
BHMT function and homocysteine metabolism have provided convincing evidence that 
suggests genetic mutations of neither MS (Jacques et al. 2003; Harmon et al. 1999; Chen et 
al. 2001; Hyndman et al. 2000) nor BHMT (Weisberg et al. 2003) are associated with 
hyperhomocysteinemia and cardiovascular disease. In fact, the most common mutation of 
MS, which is a result of the substitution of a glycine residue for an aspartic acid residue at 
base pair 2756 (A2756G), has been paradoxically associated with a decrease in plasma 
homocysteine concentrations (Chen et al. 2001). Additionally, it has been reported that 
carriers of the 2756 A->G mutation are less likely to suffer from cardiovascular disease than 
individuals with the normal genotype (Hyndman et al. 2000). 
Although no underlying mechanism has been elucidated concerning the correlation 
between MS deficiency and reduced homocysteine concentrations, it has been demonstrated 
that individuals carrying the A2756G mutation of MS exhibited elevated cystathionine levels 
when compared to the wild-type controls (Geisel et al. 2001) indicating that the removal of 
homocysteine by CPS and the transsulfuration pathway is increased during MS deficiency. 
One possible explanation for this occurrence is that a deficiency of MS results in a 
substantial build up of 5-methyl-THF levels due to the inability of MS to remethylate 
homocysteine. Because the conversion of 5,10-methylene-THF to 5-methyl-THF by 
MTHFR is an irreversible reaction (Kutzbach and Stokstad 1967; 1971), a deficiency of MS 
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could cause folate to be "trapped" as 5-methyl-THF. As 5-methyl-THF concentrations rise, 
it becomes readily available to allosterically inhibit the GNMT-dependent conversion of 
SAM to S AH, increasing SAM concentrations in the process. Therefore, homocysteine levels 
would be expected to decline considerably because increased levels of SAM, which is an 
allosteric activator of CpS, facilitate the catabolism of existing homocysteine through the 
transsulfuration pathway (Finkelstein and Martin 1986). 
Nutrient deficiency and environmental factors 
Nutrient deficiency. Deficiencies of folate, vitamin Bn, and/or vitamin Be have 
significant implications for the development of hyperhomocysteinemia. Folate and vitamin 
Bn are nutrients that are required for remethylation of homocysteine, and a deficiency of 
these nutrients has been associated with increased plasma concentrations of homocysteine 
and an increased risk for developing coronary artery disease, presumably due to insufficient 
remethylation (Kang et al. 1987; Jacob et al. 1994; Bostom et al. 1996; Selhub et al. 1993; 
Pancharuniti et al. 1994; Voutilainen et al. 2000). Likewise, vitamin Be deficiency has also 
been associated with moderate hyperhomocysteinemia (Cuskelly et al. 2001). Because 
vitamin Be is a cofactor for CpS and cystathionine y-lyase during the catabolism of 
homocysteine through the transsulfuration pathway, it seems likely that vitamin B&-
deficiency would perturb the enzymatic function of CpS and cystathionine y-lyase, and 
produce a concomitant rise in homocysteine levels. Interestingly, vitamin Be-deficiency has 
been recently identified as an independent risk factor for stroke and transient ischemic attack, 
independent of its role in the transsulfuration pathway (Kelly et al. 2003). 
Because a number of B vitamins are required for homocysteine metabolism, it seems 
plausible that a supplement containing a B vitamin complex including folate, vitamin Bn, 
and vitamin Be would be useful in the treatment of hyperhomocysteinemia. Supplementation 
with these vitamins has been effective in normalizing plasma homocysteine concentrations 
when they were given alone (Brattstrom et al. 1988; Shimakawa et al. 1997). Another 
relatively effective strategy for reducing homocysteine levels has been supplementation with 
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betaine, which has been shown to reduce homocysteine concentrations as long as the 
compound is continuously administered (Steenge et al. 2003). 
Pharmacological agents. A number of medications are known to produce increased 
plasma homocysteine levels. Drugs that are known to impair folate metabolism, such as 
antiepileptics (Schawninger et al. 1999), oral contraceptives (Steegers-Theunissen et al. 
1992), and the antifolate drug methotrexate (Refsum et al. 1989) have been linked to elevated 
plasma homocysteine concentrations. Additionally, Schulpis et al. (2001) recently 
discovered that the retinoid-containing oral acne medication, isotretinoin (13-cw-retinoic 
acid) elevated plasma homocysteine concentrations in patients treated for cystic acne, an 
occurrence that the authors suggested may have been caused by an inhibition of CPS activity 
resulting from liver dysfunction, which is a common side effect of the drug. 
Diabetes mellitus. The number one complication of diabetes is cardiovascular 
disease (Anderson 1999). Long-term exposure to hyperglycemia associated with 
uncontrolled diabetes results in enhanced glycosylation and modification of proteins, thereby 
playing a role in atherosclerosis and microvascular complications such as nephropathy and 
retinopathy. Hyperhomocysteinemia is also believed to contribute to heart disease in 
diabetics (Munshi et al. 1996). Evidence suggests that hyperhomocysteinemia is prevalent in 
diabetics with compromised renal function (Poirier et al. 2001 ; Robillon et al. 1994). 
Because renal tubular epithelial tissue is believed to play a major role in the metabolism of 
homocysteine (Foreman et al. 1982), damage to this tissue may inhibit the removal of 
homocysteine from the blood (Robillon et al. 1994). Recent evidence suggests that 
hyperhomocysteinemia due to renal failure may also be due to altered remethylation of 
homocysteine due to decreased MTHFR activity in the kidney (Poirier et al. 2001). 
The importance of the kidney in homocysteine metabolism is further explained in 
diabetics who are not suffering from nephropathy. The opposite effect (i.e., enhanced 
homocysteine metabolism) commonly occurs in these diabetics, and homocysteine levels are 
reduced when compared with non-diabetic subjects (Cronin et al. 1998). It has been 
postulated that the enhanced metabolism of plasma homocysteine in these diabetics is due to 
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renal hyperfusion and increased homocysteine catabolism in the renal tubular epithelium 
(Robillon et al. 1994). 
Growing evidence suggests that the hormonal up-regulation of the transsulfuration 
pathway by counter-regulatory hormones (i.e., glucagon and glucocorticoids) also plays a 
major role in reducing circulating homocysteine levels during diabetes (Jacobs et al. Ratnam 
et al. 2002). Variations of circulating insulin levels as well as surging counter-regulatory 
hormone concentrations in the plasma are common complications associated with 
uncontrolled diabetes. During uncontrolled diabetes, counter-regulatory hormones are 
released into the bloodstream as a result of insufficient glucose uptake and cellular utilization 
caused by either poor insulin production by the pancreas or insulin insensitivity. The ability 
of counter-regulatory hormones to produce a catabolic state contributes to the complications 
of diabetes by causing substrates, such as glucose and fatty acids, to be released into the 
bloodstream in an effort to compensate for insufficient cellular glucose utilization. Recent 
studies have demonstrated that increased counter-regulatory hormone levels also have the 
ability to up-regulate homocysteine catabolism by increasing gene expression of key 
enzymes involved in the transsulfuration pathway (Jacobs et al. 1998; Jacobs et al. 2001 ; 
Ratnam et al. 2002). Jacobs et al. (2001) reported that glucagon administration to rats led to 
a 30% decrease in plasma homocysteine levels and a concomitant 75 and 29% increase in 
hepatic CpS and cystathionine y-lyase activity, respectively. The increase in CpS activity in 
these animals was reflected by increased abundance of both CPS mRNA and protein, 
occurrences that were prevented by insulin treatment, indicating that modulation of CPS by 
glucagon occurs, at least in part, at the transcriptional level. In an expansion of the 
experiments with glucagon, Ratnam et al. (2002) demonstrated that glucocorticoid-treated 
H4IIE rat hepatoma cells and livers of streptozotocin-diabetic rats also exhibited an increase 
of CpS protein and mRNA abundance. Similar to the studies with glucagon-treated rats, 
induction of CPS protein and mRNA abundance in rats and hepatoma cells by 
glucocorticoids was prevented by insulin treatment. Moreover, treatment of Hep G2 human 
hepatoma cells with insulin also reduced CPS mRNA levels. Taken together, these findings 
clearly indicate that CPS expression can be modulated at the transcriptional level by 
hormonal factors that are central to glucose metabolism. 
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In addition to inhibiting the removal of homocysteine through the transsulfuration 
pathway, insulin appears to have a similar effect on the remethylation system. Dicker-Brown 
et al. (2001) demonstrated in Hep G2 cells that insulin inhibited both C|3S and MTHFR 
activity in a similar fashion, making it apparent that insulin inhibits the two major pathways 
of homocysteine metabolism. Therefore, it is possible that diabetics with renal failure who 
are on insulin therapy may be at an increased risk for extreme cases of hyperhomo­
cysteinemia. 
Carcinogenesis 
Hypomethylated DNA 
An adequate dietary supply of folate and methyl groups has long been known to be 
essential for the prevention of cancer (Newberne and Rogers 1986). Diets that are deficient 
in methyl groups have been shown to lead to the spontaneous development of 
hepatocarcinogenesis in rats (Salmon and Copeland 1954; Ghoshal and Farber 1984). 
Although it is not totally clear how methyl deficiency induces carcinogenesis, several studies 
have discovered a strong correlation between impaired methylation of DNA and increased 
cancer incidence in methyl-deficient animals (Wainfan et al. 1989; Bhave et al. 1988; 
Wainfan and Poirier 1992). The methylation of DNA is believed to have a significant role in 
the prevention of neoplastic development through its ability to control gene expression (Jones 
and Takai 2001) and stabilize chromosomes (Baylin, et al. 1998). Bhave et al. (1988) 
examined the importance of DNA methylation in the prevention of hepatocarcinogenesis and 
discovered an increased incidence of hypomethylated oncogenes in methyl deficient rats. 
Oncogenes represent regions of DNA where increased gene expression is associated with 
uncontrolled cell replication and tumor development, and hypomethylation of these regions 
has been positively correlated with their expression in rats (Wainfan and Poirier 1992). 
S AH and DNA hypomethylation 
Hypomethylated DNA due to a deficiency of activated methyl groups (i.e., SAM) has 
been postulated to be partially responsible for tumor formation in liver tissue (Pascale et al. 
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1992); however, recent evidence argues that the intracellular concentration of S AH may be 
the most sensitive biomarker for cellular methylation status (Caudill et al. 2001). It is known 
that a deficiency of methyl groups results in a decrease of hepatic SAM concentrations and 
the SAM/SAH ratio, and a concomitant rise in hepatic S AH levels (Shivapurkar and Poirier 
1983). Because S AH inhibits most methyl transfer reactions (Kerr 1972), increased S AH 
levels have obvious implications for the inhibition of DNA methylation. In fact, it has 
recently been reported that CpS heterozygous mice with elevated hepatic S AH 
concentrations exhibit global DNA hypomethylation in the liver (Caudill et al. 2001). The 
conversion of homocysteine back to S AH is kinetically favored, therefore; inhibition of DNA 
methylation could be an indirect consequence of increased homocysteine concentrations. 
Hypomethylated DNA has also been discovered in folate-deficient rats (Balaghi and Wagner 
1993), animals that may have experienced increased homocysteine levels due to decreased 
folate-dependent remethylation, a common occurrence during folate deficiency (Kang 1987). 
Hence, increased homocysteine levels and the simultaneous decrease of de novo methionine 
synthesis due to folate deficiency may inhibit DNA methylation by 1) decreasing the supply 
of available methyl groups for the methylation of DNA and/or by 2) increasing S AH levels. 
DNA strand breaks 
It has been hypothesized that DNA strand breaks, which are known to occur as a 
result of genomic instability (Piyathilake and Johanning 2002), lead to the induction of 
carcinogenesis during methyl group- and/or folate deficiency (Blount et al. 1997). Evidence 
suggests that this occurrence may be related to structural changes of DNA resulting from a 
dUTP substitution for dTTP during DNA synthesis (Duthie et al. 2002; Kim et al. 1997; 
Blount et al. 1997) or from cytosine deamination to dUTP in existing DNA (Lindahl 1993). 
As described earlier, the conversion of uridylate to thymidylate requires the donation of a 
methylene group from the folate derivative 5,10-methylene-THF. Thus, a deficiency of this 
folate coenzyme may cause imbalances in the DNA precursor pool and lead to an increased 
incidence of dUTP incorporation into DNA and subsequent strand breakage (Blount et al. 
1997). 
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The regions of DNA where strand breaks occur appears to be a significant factor that 
determines whether or not they contribute to neoplastic development. For instance, it is 
known that strand breaks occurring at the region of DNA encoding the p53 tumor suppressor 
gene readily occur during folate deficiency (Kim et al. 1997). Strand breaks at the p53 gene 
have been linked to neoplastic development in the colon and esophagus (Hollstein et al. 
1991). Moreover, strand breaks and uracil misincorporation into the p53 gene of hepatic 
DNA have been shown to be prevalent in folate/methyl-deficient rats exhibiting 
preneoplastic hepatic lesions (Pogribny et al. 1997). 
Hepatocarcinogenesis and methyl group deficiency 
The liver possesses high levels of enzymes involved in one-carbon metabolism 
(Finkelstein 1990). Therefore, it seems likely that if certain cancers were caused by a 
perturbation of one-carbon metabolism, they would be present in the liver. Aberrant one-
carbon metabolism due to malnutrition may be a major contributor to hepatocarcinogenesis 
in humans (Giovannucci et al. 1993). Additionally, epidemiological and clinical evidence 
suggests that the consumption of foods contaminated with carcinogens, such as mycotoxins, 
some of which are known to perturb one-carbon metabolism (Ueno et al. 1997), leads to the 
high prevalence of hepatocarcinogenesis in regions where food-borne fungi are more 
prevalent (Ueno et al. 1997). Thus, examining the relationship between certain carcinogens 
and one-carbon metabolism has been a useful tool in determining the role of methyl groups 
in preventing hepatocarcinogenesis. Newbeme et al. (1990) demonstrated that supplemental 
methionine and choline reduced the incidence of liver cancers in mice given a carcinogenic 
dose of aflatoxin Bi, a mycotoxin commonly found in contaminated grain. Similar results 
were found in studies where rats were exposed to diethylnitrosamine (DENA), a cancer-
initiating agent (Pascale et al 1992; Porta et al 1985). In addition, Hoover et al. (1984) 
discovered that DENA-induced hepatocarcinogenesis was exacerbated in methyl-deficient 
rats. Taken together, these findings suggest supplemental methyl groups and/or folate could 
be useful in reducing the incidence of diet-related cancers. 
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Neurological Disorders 
SAM is utilized in the brain for the synthesis of neurotransmitters such as dopamine, 
serotonin, and norepinephrine. Recent evidence suggests that the role of SAM during the 
synthesis of neurotransmitters is important for the prevention of symptoms related to 
depression (Mishoulon and Fava 2002). In fact, evidence collected from trial studies 
suggests that the efficacy of oral SAM administration in treating depression is comparable to 
that of tricyclic antidepressants (Bressa 1994). Based in part on such findings, SAM is now 
marketed as an alternative to prescription anti-depressant medications and is available as an 
over-the-counter dietary supplement (Mischoulon and Fava 2002). 
Folate (Bottiglieri et al. 1992; Reynolds et al. 1970) and vitamin Bn deficiency 
(Botez et al. 1982) have also been linked to depression; however, the mechanistic basis of 
these findings is yet to be determined. Since vitamin Bn and folate are required for the de 
novo synthesis of SAM, it is possible that depression associated with a deficiency of these 
nutrients is due, at least in part, to a decline in the synthesis of neurotransmitters. 
In addition to depression, a number of other neurological disorders have been 
associated with folate deficiency including, polyneuropathy (Botez et al. 1978; Grant et al. 
1965), Alzheimer's disease, and Parkinson's disease (Mattson and Shea 2003). These 
disorders are a currently a topic of intense research. Evidence suggests that a disruption of 
homocysteine metabolism due to folate deficiency may contribute to the progression of such 
diseases by leading to decreased function and atrophy of neurotransmitter-producing neurons 
(Mattson 2003). 
Megaloblastic Anemia and the "Methyl Trap" Hypothesis 
The relationship between folate and vitamin Bn is critical during the MS-dependent 
remethylation of homocysteine by 5-methyl-THF, the only reaction known to require both 
folate and vitamin Bn (Hatch et al. 1961). Because the conversion of 5,10-methylene-THF 
to 5-methyl-THF by MTHFR is physiologically irreversible (Kutzbach and Stokstad 1971), it 
is therefore essential that an adequate supply of vitamin Bn is available to ensure that normal 
functioning of MS is maintained and to avoid what is known as the "methyl trap". During 
vitamin Bn deficiency, a "functional folate deficiency" occurs where the supply of folate 
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becomes trapped as 5-methyl-THF (Shane and Stokstad 1985), and tissue concentrations of 
other folate coenzymes, such as those used for the synthesis of DNA precursors, declines. A 
pathological condition that commonly results from a deficiency of either folate or vitamin 
B12 is megaloblastic anemia. Megaloblastic anemia is characterized by the appearance of 
large undifferentiated erythroblasts in circulation and a reduction in the number of circulating 
erythrocytes, which are believed to be due to decreased DNA synthesis and poor cell division 
(Hofïbrand et al. 1976). Depending on their respective nutrient deficiency, individuals 
suffering from megaloblastic anemia should be provided with supplemental folate or vitamin 
Bi2. It has been hypothesized that supplementary methyl groups may also help alleviate 
symptoms of megaloblastic anemia through their ability to spare folate coenzymes from 
being trapped as 5-methyl-THF through SAM-mediated inhibition of MTHFR (Shane and 
Stokstad 1985). 
Impaired Pancreatic Function 
Folate deficiency has been shown to inhibit pancreatic function (Balaghi and Wagner 
1992; 1995; Elseweidy and Singh 1984), which appears to be due to the inhibition of SAM-
dependent methylation of proteins that are responsible for the secretion of enzymes such as 
amylase (Capdevila et al. 1997). These findings obviously have serious implications for the 
disruption of normal digestion in folate-deficient individuals, alcoholics, and those using 
drugs that produce side effects that alter folate and methyl group metabolism. 
Drugs and Toxins 
As previously mentioned, pharmacological agents and environmental toxins can have 
a major impact on one-carbon metabolism,. Summarized below are some important findings 
regarding the effect of various toxicants on methyl group and/or folate-dependent, one-
carbon metabolism. 
Retinoids 
Vitamin A compounds, collectively referred to as retinoids, are utilized as therapeutic 
agents in the treatment of a number of conditions, including cystic acne and leukemia. 
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However, commonly prescribed in medications containing pharmacological doses of retinoid 
compounds have been shown to produce side effects that may be related to a disruption of 
one-carbon metabolism (Schulpis et al. 2001). Retinoid therapy is contraindicated with 
respect to pregnancy because of its association with an increased incidence of neural tube 
defects and other congenital malformations (Lammer et al. 1985), conditions associated with 
abnormal one-carbon metabolism. Studies that examined the ability of retinoids to alter the 
distribution of folate coenzymes in the one-carbon pool showed that the activity of hepatic 
MTHFR was inhibited in rats treated with pharmacological doses (1,000 IU/g diet) of retinol 
(vitamin A), which in turn resulted in decreased 5-methyl-THF synthesis (Fell and Steele 
1986). Furthermore, the oxidation rate of formate to COa was increased in these animals, 
indicating that retinol administration increased the catabolism of one-carbon units in the 
folate-dependent one-carbon pool. Retinol-treated rats also exhibited a reduction of hepatic 
SAM levels and the SAM/SAH ratio (Fell and Steele 1986). Similarly, Peng and Evenson 
(1982) found that retinol treatment increased the oxidation rate of the methyl group from 
methionine to CO2 in rats. 
An inhibition of SAM-dependent transmethylation reactions has been determined to 
be a consequence of retinoid-mediated depletion of SAM and a decreased SAM/SAH ratio 
(Fell and Steele 1987). In an extension of their earlier work (Fell and Steele 1986), Fell and 
Steele (1987) demonstrated that decreased hepatic levels of SAM due to retinol 
administration resulted in a reduction of the SAM-dependent conversion of phosphatidyl 
ethanolamine to phosphatidyl choline in rats, indicating that high intakes of retinoid 
compounds do in fact have the potential to impair SAM-dependent transmethylation 
reactions. Moreover, treatment with 13-cw-retinoic acid [isotretinoin (CRA)], a synthetic 
retinoid commonly used for treatment of cystic acne, reduced the hepatic concentration of 
SAM and the SAM/SAH ratio in rats (Schalinske and Steele 1991). Such findings linking 
retinoids to perturbations of one carbon metabolism clearly have importance for individuals 
receiving therapeutic retinoids for treatment of medical conditions. Interestingly, depression 
has been mentioned as a potential side effect of retinoid-containing acne medication (Enders 
and Enders 2003), which may be due, at least in part, to a decrease in the SAM-dependent 
synthesis of neurotransmitters. Other side effects of retinoid administration associated with 
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altered one-carbon metabolism include elevated plasma homocysteine levels (Schulpis et al. 
2001) and hepatic steatosis (Schalinske and Steele 1993), a condition that may be related to 
the decreased SAM-dependent synthesis of phosphatidyl choline, a phospholipid utilized for 
membrane synthesis of apolipoproteins and excretion of hepatic lipid via LDL. 
Retinoid compounds typically exert their actions at the transcriptional level via 
retinoid response elements; however, the mechanism through which retinoids alter the methyl 
group supply remains unclear. There is currently no evidence that indicates that retinoid 
response elements exist on the promoter regions of genes that encode key enzymes involved 
in methyl group metabolism. This suggests that the action of retinoids on the methyl group 
supply may occur, at least in part, at the translational and/or posttranslational level. 
Interestingly, increased catabolism of methionine caused by retinol treatment was prevented 
in adrenalectomized rats (Peng and Evenson 1982), indicating that the secretion of hormones, 
such as glucocorticoids from the adrenal glands, may play a mediating role between retinoids 
and the increased catabolism of methyl groups. Glucocorticoids and retinoids (Singh et al. 
1976) are both known to enhance the gene expression of gluconeogenic enzymes including 
phosphoenolpyruvate carboxykinase (PEPCK) (Singh et al. 1976; Pan et al. 1990; Shin and 
McGrane 1997), the rate-limiting enzyme of gluconeogenesis. Because methionine is 
catabolized to pyruvate during gluconeogenesis, it is possible that methionine catabolism is 
increased during retinoid treatment through the induction of a gluconeogenic state. 
Ethanol 
Folate deficiency is a common clinical sign of alcoholism (Halsted et al. 2002). A 
number of animal studies have demonstrated that in addition to inadequate dietary intake of 
folate, folate deficiency may be caused by increased excretion as well as elevated catabolism 
of folate coenzymes in alcoholics. Studies examining the effect of chronic ethanol exposure 
on folate metabolism demonstrated that ethanol 1) increased the catabolism of folate in the 
kidney (Eisenga et al. 1989), 2) increased urinary folate excretion in a dose- and time-
dependent manner (McMartin et al. 1986; 1986) through the inhibition of folate reabsorption 
by the renal tubules (McMartin et al. 1989), and 3) inhibited intestinal absorption of folate 
(Halsted et al. 1967; Romero et al. 1981). 
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In addition to the disruption of one-carbon metabolism through its effect on folate, 
exposure to ethanol also appears to enhance the catabolism of methionine (Trimble et al. 
1993). Trimble et al. (1993) reported that rats fed 42% of their calories as ethanol exhibited 
symptoms associated with an increased oxidation rate of methyl groups. When compared to 
control rats, ethanol-treated rats exhibited a 2.9-fold increase in the oxidation of the methyl 
group from methionine in the liver, a ~4-fold increased turnover of methyl groups from 
choline, and a 69% reduction of hepatic SAM levels. Likewise, Halsted et al. (2002) reported 
that ethanol-fed micropigs exhibited a decreased SAM/SAH ratio, an increased prevalence of 
DNA strand breaks, and elevated plasma homocysteine levels even when they were provided 
with supplemental folate. 
Clearly, the effect of chronic ethanol exposure on increased catabolism of methyl 
groups has the potential for producing pathological consequences; however, the mechanistic 
relationship between ethanol and methyl group metabolism is not well understood. Trimble 
et al. (1993) suggested that ethanol-mediated catabolism of methyl groups occurs in order to 
provide the carbon skeleton of methionine for its conversion in the transsulfuration pathway 
to glutathione, a natural antioxidant that appears to be depleted as a result of ethanol-induced 
oxidative damage to the liver. 
Anticonvulsants 
Long-term use of anticonvulsants, which has been associated folate deficiency 
(Dansky et al. 1987) and aberrant one-carbon metabolism (Alonso-Aperte et al. 1999) has 
also been associated with megaloblastic anemia (Hawkins and Meynell 1958) and congenital 
malformations during pregnancy (Dansky et al. 1987). Anticonvulsants, including the drugs 
phenytoin, phenobarbitone, phénobarbital, primidone, carbamazepine, and valproate, are 
thought to exert their actions on folate-dependent one-carbon metabolism by interfering with 
intestinal folate absorption (Meynell 1966; Hoffbrand and Necheles 1968) and/or inducing 
hepatic enzymes involved in the degradation of folate (Labadarios et al. 1978; Kishi et al. 
1997). Valproate in particular, has been shown to be a potent disrupter of methyl group 
metabolism, which appears to be due, at least in part, to its ability to alter the methyl group 
supply (Alonso-Aperte et al. 1999; Carl 1986). 
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Oral contraceptives 
The use of oral contraceptives has been associated with reduced serum folate levels 
(Pietarinen et al, 1977) and megaloblastic anemia (Baroné et al, 1979), conditions that are 
consistent with both increased plasma clearance of folate and elevated urinary folate 
excretion (Shojania et al. 1975). Stitterlin et al. (2003) recently reported that oral 
contraceptives also lower vitamin Bn levels, which may put individuals using these 
medications at even more of an increased risk for developing megaloblastic anemia and other 
conditions associated with impaired folate metabolism. 
Fumonisins 
Fumonisins are mycotoxins found primarily in contaminated com that have been 
shown to produce alterations of folate metabolism (Carratû et al, 2003). Fumonisins are 
thought to disrupt folate metabolism by blocking folate transport into the cell by inhibiting 
the synthesis of sphingolipids (Carratû et al, 2003), molecules required for cell membrane 
synthesis and cell signaling. Exposure to fumonisin Bi has been implicated in a number of 
pathologies commonly observed during folate deficiency, such as neural tube defects 
(Hibbard 1993) and liver cancer (Ueno et al. 1997). Therefore, it is not surprising that folic 
acid supplementation has been shown to be protective against these fumonisin-related 
pathologies (Sadler et al. 2002). 
Glycine JV-methyltransferase (GNMT) 
Glycine JV-methyltransferase (GNMT) is a cytosolic protein found primarily in the 
liver, pancreas, and kidney (Yeo and Wagner 1994) that functions to regulate the methyl 
group supply by disposing of excess methyl groups and controlling of the SAM/SAH ratio. 
GNMT is an especially abundant protein, constituting 1-3% of total cytosolic protein in the 
liver (Heady and Kerr 1975), suggesting that its role in regulating the methyl group supply is 
of major biological significance. The physiological importance of GNMT has been 
illustrated in clinical and metabolic studies (Mudd et al. 2001; Luka et al. 2002), where it 
was discovered that mild liver disease, persistent hypermethioninaemia, and elevated SAM 
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concentrations were present in siblings carrying a rare mutation that causes GNMT 
deficiency. 
The importance of GNMT in one-carbon metabolism is a relatively new research 
area. Hence, it is currently unknown how GNMT deficiency or perturbations of GNMT 
affect other SAM-dependent transmethylation reactions. It is also unclear how physiological 
factors can alter GNMT expression. It is understood that enzymatically active GNMT (132 
kDa), a tetrameric protein comprised of 4 identical subunits (Ogawa and Fujioka 1982), can 
be modulated at the postradiational level through the phosphorylation of each GNMT 
subunit by cAMP-dependent protein kinases, which serves to increase the enzymatic activity 
of the protein (Wagner et al. 1989). Additionally, GNMT's role as a folate-binding protein 
allows it to be allosterically inhibited by 5-methyl-THF, as discussed earlier. It is unclear, 
however, whether GNMT activity is modulated at the transcriptional or translational levels. 
GNMT activity is elevated during diabetes (Xue and Snoswell 1985), a condition that is 
associated with increased levels of glucagon and glucocorticoids, counterregulatory 
hormones that induce gluconeogenesis. As previously described, these hormones have been 
shown to increase the expression of other key enzymes in methyl group metabolism at the 
transcriptional level. Because the presence of GNMT is essentially limited to gluconeogenic 
tissues (Yeo and Wagner 1994), it is possible that counterregulatory hormones also play a 
role in regulating GNMT gene expression. 
In our laboratory, I have examined the role of GNMT in mediating the perturbation of 
methyl group metabolism by retinoid compounds and have illustrated for the first time that 
the modulation of GNMT is regulated, at least in part, at the transcriptional/translational 
levels by vitamin A compounds and glucocorticoids. I have also reported that retinoid-
mediated GNMT induction leads to impaired SAM-dependent transmethylation reactions 
(i.e. DNA methylation). Furthermore, I have shown that homocysteine metabolism is altered 
by retinoids and glucocorticoids. In the following chapters, original research articles that 
have been published in peer-reviewed journals discuss our observations in greater detail. 
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RETINOID COMPOUNDS ACTIVATE AND INDUCE HEPATIC 
GLYCINE iV-METHYLTRANSFERASE 
IN RATS12 
A paper published in the Journal of Nutrition3 
Matthew J. Rowling4 and Kevin L. Schalinske 4,5 
Abstract 
Glycine /V-methyltransferase (GNMT) functions to regulate S-adenosylmethionine 
(SAM) levels and the ratio of SAM/ S-adenosylhomocysteine (SAH). SAM is a universal 
methyl group donor and up-regulation of GNMT may lead to wastage of methyl groups 
required for transmethylation reactions. Previously, we demonstrated that dietary treatment 
of rats with 13-cw-retinoic acid (CRA) decreased the hepatic concentration of SAM and the 
SAM/SAH ratio. Here, we examined the ability of CRA, as well as all-Zra/iy-retinoic acid 
(ATRA), to regulate hepatic GNMT as a potential basis for our earlier observations. Rats 
were fed either a control (10% casein + 0.3% L-methionine) diet or a control diet 
supplemented with L-methionine (MS, 10 g/kg diet). Animals from each group were orally 
given either ATRA, CRA (both @ 30 pmol/kg body weight), or vehicle daily for 7 d. For 
control rats, administration of both CRA and ATRA elevated the hepatic GNMT activity 49 
and 34%, respectively, compared to the control group. Similar results were exhibited by rats 
fed the MS diet. Moreover, the retinoid-induced elevations in enzymatic activity were 
reflected in the abundance of GNMT protein. To our knowledge, this is the first report of a 
nutritional compound that induces GNMT activity at the transcriptional and/or translational 
level. 
Key Words: retinoic acid • S-adenosylmethionine • transmethylation 
• glycine N-methyltransferase • rats 
38 
Footnotes 
'Supported in part by: Iowa Agriculture & Home Economics Experiment Station (Journal 
Paper No. J-19189); the Iowa State University Office of Biotechnology; the Center for 
Designing Foods to Improve Nutrition (USD A Special Projects Grant 99-03168); USD A 
NRI01-35200-09854 (to K.L.S.); and the American Institute for Cancer Research 
OOB078REV (to K.L.S.). 
2A preliminary report of this manuscript was presented at Experimental Biology 2001, 
Orlando, FL [Rowling, M.J. & Schalinske, K.L. (2001) Glycine N-methyltransferase is up-
regulated by ail-trans- and 13-cw-retinoic acid in rats. FASEB J. 15: A602 (abs.)]. 
^Reprinted with permission of J. Nutr., 2001,131,1914-1917. 
^Graduate student and assistant professor, respectively, Department of Food Science and 
Human Nutrition. 
5TO whom correspondence should be addressed: Kevin L. Schalinske, Department of Food 
Science and Human Nutrition, Iowa State University, 220 MacKay Hall, Ames, IA, 50011, 
515-294-9230 (tele), 515-294-6193 (fax), kschalin@iastate.edu (Email). 
6Abbreviations used: ATRA, all-fraws-retinoic acid; BSA, bovine serum albumin; CRA, 13-
c/j-retinoic acid; GAR-HRP, goat anti-rabbit horseradish peroxidase; GNMT, glycine N-
methyltransferase; MS, methionine-supplemented; MTHFR, 5,10-methylene-tetrahydrofolate 
reductase; PMSF, phenylmethylsulfonylflouride; PEPCK, phosphoenolpyruvate 
carboxykinase; S AH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, 
tetrahydrofolate; TTBS, tween-tris-buffered saline. 
39 
Introduction 
Methyl groups supplied from dietary methionine or choline are required for the 
synthesis of S-adenosylmethionine (SAM6), a vital compound that is required as a substrate 
in SAM-dependent transmethylation reactions (1,2) (Figure 1). SAM-dependent 
transmethylation reactions include the posttranslational modification of nucleic acids and 
proteins (3), and the synthesis of important molecules such as neurotransmitters, 
phospholipids, and nucleic acids (1,2). Therefore, a lack of dietary methyl groups from the 
diet or the folate-dependent one-carbon pool can result in pathological conditions. A 
deficiency of dietary methyl groups leads to hepatocarcinogenesis (4,5), a condition that may 
be due to hypomethylated DNA (6). Additionally, folate deficiency down-regulates SAM-
dependent transmethylation reactions (7) and has been implicated in a number of related 
pathologies (8). 
Glycine AT-methyltransferase (GNMT) is a key cytosolic protein that controls the 
intracellular supply of available methyl groups for SAM-dependent transmethylation 
reactions (9). GNMT is known to dispose of excess SAM as sarcosine, a product that has no 
known metabolic function, thus controlling the SAM/S-adenosylhomocysteine (SAH) ratio, 
an index of transmethylation potential due to the ability of SAH to inhibit the majority of 
methyltransferases (9). The activity of GNMT is controlled by a number of regulatory 
mechanisms that are dependent on methyl group supply. For instance, when an abundant 
intracellular supply of SAM exists, SAM serves to allosterically inhibit 5,10-
methylenetetrahydrofolate reductase (MTHFR) (10,11), an enzyme that catalyzes the 
irreversible conversion of 5,10-methylene-tetrahydrofolate (5-MTHFR) to 5-methyl-
tetrahydrofolate (5-methyl-THF). Because GNMT serves as a folate-binding protein that is 
inhibited by 5-methyl-THF, decreased synthesis of 5-methyl-THF facilitates the disposal of 
excess SAM by GNMT. In contrast, a lack of SAM results in the increased synthesis of 5-
methyl-THF, which in turn inhibits GNMT (12) and thus allows SAM to serve as a substrate 
in important transmethylation reactions. Collectively, these regulatory mechanisms serve to 
optimize the methyl group supply; therefore, factors that can disturb the function of GNMT 
may have pathological consequences with respect to folate and methyl group metabolism. 
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Previous work in our laboratory has demonstrated that the administration of 13-cis-
retinoic acid (CRA), a retinoid compound commonly used therapeutically for the treatment 
of cystic acne, alters methyl group metabolism by reducing hepatic SAM concentrations and 
the SAM/SAH in rats treated with CRA (13). In an effort to understand the role of retinoids 
in the increased catabolism of methyl groups, we focused on the activation of GNMT as a 
potential mechanism. Additionally, we examined the ability all-/ra«s-retinoic acid (ATRA), 
the biologically active form of vitamin A commonly prescribed for treatment of certain types 
of leukemia, to perturb methyl group metabolism. 
Materials and Methods 
Chemicals and Reagents. 
Reagents were obtained from the following: S-adenosyl-L-[me?fty/-3H]methionine, 
New England Nuclear (Boston, MA); phenylmethylsulfonylflouride (PMSF), Calbiochem 
(La Jolla, CA); goat anti-rabbit IgG horseradish peroxidase (GAR-HRP), Southern 
Biotechnology (Birmingham, AL); ECL™ Western blotting detection reagents, Amersham 
Pharmacia (Piscataway, NJ); and S-adenosyl-L-methionine, Sigma Chemical Co. (St. Louis, 
MO). GNMT antibody was kindly provided by Conrad Wagner, Vanderbilt University. 
ATRA and CRA were provided courtesy of Hoffinann-LaRoche (Nutley, NJ). All other 
chemicals were of analytical grade. 
Animals and Diets. 
All animal experiments were approved by and conducted in accordance with Iowa 
State University Laboratory Animal Resources Guidelines. Male Sprague Dawley (Harlan 
Sprague Dawley, Indianapolis, IN) rats were housed in suspended wire-mesh cages in a room 
with a 12-h light: dark cycle and given free access to food and water. The composition of the 
control diet was the same as previously described (13). The methionine-supplemented (MS) 
diet contained additional L-methionine (10 g/kg diet) at the expense of glucose monohydrate. 
Following an 11-d acclimation period during which rats were adapted to both the 
control diet and oral administration of corn oil, they were divided into six treatment groups 
consisting of five rats per group. Rats were fed one of the two diets (control or MS) and 
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were orally administered either vehicle (corn oil, 1 pL/g body weight), vehicle containing 
CRA, or vehicle containing ATRA daily. Both retinoids were administered at a level of 30 
jumol/kg body weight. Following the 7-d treatment period, rats were anesthetized and liver 
samples were rapidly removed for analysis. 
Measurement of GNMT activity. 
The enzymatic activity of GNMT was assayed as described by Cook and Wagner (14) 
with minor modifications. Portions of liver were homogenized in 3 volumes of ice-cold 
phosphate buffered (10 mmol/L, pH 7.0) sucrose (0.25 mol/L) containing 1 mmol/L EDTA, 
1 mmol/L sodium azide, and 0.1 mmol/L PMSF. Following centrifugation at 20,000 x g for 
30 min, the resulting supernatant was removed and 2-mercaptoethanol was added to a final 
concentration of 10 mmol/L. The assay mixture consisted of 0.1 mol/L Tris buffer (pH 9.0), 
5 mmol/L dithiothreitol, 1 mmol/L glycine, and 1 mmol/L S-adenosyl-L- [methyl-
3H]methionine (4.77 x 106 Bq/mmol). The reaction was initiated upon addition of 250 |ig of 
sample protein. The assay was linear with respect to time and protein concentration. For the 
determination of total soluble protein in the tissue extract, a commercial kit (Coomassie Plus, 
Pierce, Rockford, IL) based on the method of Bradford (15) was used with bovine serum 
albumin (BSA) as a standard. 
Measurement of GNMT Protein. 
For the determination of the abundance of GNMT protein, immunoblotting with 
chemiluminescence detection was employed. SDS-polyacrylamide gel electrophoresis was 
performed using a 10-20% gradient gel and 75 pg sample protein per lane. Following 
separation, the proteins were electrophoretically transferred to nitrocellulose and the 
membrane was incubated at room temperature in a blocking solution containing nonfat dry 
milk (5 g/100 mL) in TTBS buffer consisting of 20 mmol/L Tris, (pH 7.5) and 500 \i\FL 
Tween 20. Affinity-purified polyclonal GNMT antibody in BSA (1 g/100 mL) - TTBS 
(1:1000) was added and the blot was incubated at 4°C overnight. The blot was incubated for 
1 h at room temperature with GAR-HRP in TTBS (1:5000), followed by a 1-min incubation 
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in Western blot chemiluminescent detection reagents prior to multiple exposures to 
autoradiography film. Densitometric analysis was performed using the NIH Image software. 
Statistical Analysis. 
The means of each treatment group were subjected to a two-way ANOVA. When the 
ANOVA proved to be significant (P < 0.05), the means were compared using the Fisher LSD 
procedure (16). 
Results 
Retinoid treatment did not alter rat growth rates. 
Body weights were measured during both the acclimation phase (data not shown) and 
retinoid-treatment period of the study (Fig. 2). All rat groups exhibited similar growth 
patterns regardless of treatment and no significant differences were detected in either the 
initial (81 ± 2 g) or final (181 ± 3 g) body weights. As indicated in Fig. 2, no significant 
differences were observed in the cumulative weight gain across the treatment groups, 
indicating that neither the MS diet nor the retinoids were overtly toxic to the animals. We 
have shown previously that administration of CRA does have the ability to induce hepatic 
steatosis in rats fed a similar diet (13). This was also found to be the case in the present 
study for both CRA and ATRA (data not shown). 
Retinoids increased the enzymatic activity of hepatic GNMT. 
As shown in Fig. 3, administration of CRA and ATRA consistently elevated the 
enzymatic activity of hepatic GNMT. For rats receiving the control diet, CRA administration 
increased GNMT activity 49%. ATRA also increased enzyme activity (34%), however, this 
change was not statistically significant (P=0.081). In contrast, both CRA and ATRA 
significantly induced GNMT activity 41 and 45%, respectively, in rats receiving the MS diet. 
For the MS diet, the addition of L-methionine alone (10 g/kg diet) was without significant 
effect. Previous studies have demonstrated that induction of GNMT activity by dietary 
methionine requires closer to 20 g methionine/kg diet (17). 
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Both CRA and ATRA induce GNMT protein abundance. 
Using immunoblotting with a GNMT antibody, we determined whether the retinoid-
induced increase in GNMT activity was due to changes in the production of the enzyme (Fig. 
4). The bar graph reflects the mean result from all of the experimental animals, whereas the 
immunoblot shown above is a representative example with the relative fold induction shown 
for each lane. Both CRA and ATRA markedly induced GNMT protein abundance in control 
rats and animals receiving the MS diet. The induction of GNMT protein by retinoids across 
treatment groups ranged from approximately 8- to 16-fold. Similar to the enzyme activity 
data, the MS diet alone did not significantly alter GNMT protein levels based on mean 
values. However, it does appear to have some effect as can be seen in the representative blot 
(3.1-fold induction). There was no difference in actin protein abundance across the treatment 
groups. Interestingly, in both the bar graph and representative immunoblot, the effect of the 
MS diet and retinoids on GNMT protein induction appears to be additive. As suggested by 
others (17), we have directly confirmed that the addition of graded levels of L-methionine to 
the diet and subsequent induction of GNMT enzyme activity is reflected in an increase in 
GNMT protein abundance (Rowling and Schalinske, unpublished data). 
Discussion 
GNMT serves a crucial role in methyl group- and folate-dependent one-carbon 
metabolism by regulating the methyl group supply and the SAM/SAH ratio (9). Hence, 
factors that can disrupt the function of this enzyme may produce deleterious physiological 
consequences. We have demonstrated that the vitamin A derivatives have the ability to 
activate GNMT, which was reflected by the abundance of the protein. Thus, we have 
demonstrated for the first time, at least to our knowledge, that GNMT can be modulated at 
the transcriptional/translational level. Furthermore, we have clearly shown that ATRA, the 
active form of vitamin A, has a similar ability to CRA in altering methyl group metabolism. 
Our observations with CRA and ATRA have clear implications for those individuals 
receiving therapeutic retinoids for medical conditions such as skin disorders and leukemia. 
Although we administered these compounds to our animals in pharmacological doses (30 
pmol/kg) that are far above the clinical dosage normally prescribed to humans receiving 
retinoid therapy (2-6 pmol/kg), we have discovered that doses as low as 1 pmol/kg have a 
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similar ability to activate and induce GNMT protein in rats (Rowling and Schalinske, 
unpublished observations). Additionally, rats are known to be less sensitive to CRA than 
humans due to their increased ability to eliminate the drug (18), indicating that doses used in 
our studies may be more effective in perturbing methyl group metabolism in humans. Thus, 
humans receiving retinoids for therapeutic use may be at an increased risk for developing 
complications related to methyl group metabolism even when given low doses of retinoid 
compounds. 
A number of factors have been shown to increase the activity of GNMT at the 
posttranslational level, including folate deficiency (7), ethanol administration (19), and 
phosphorylation of the protein by cyclic adenosine 5'-monophosphate (cAMP)-dependent 
kinases (20). The present study raises a number of questions concerning the regulation of 
GNMT protein synthesis by retinoids. Because there is no known retinoid response element 
in the promoter region of the GNMT gene, it is possible that the apparent induction of 
GNMT in our studies was a result of either increased translation or stabilization of the 
protein. It is known that in addition to its enzymatic function as a tetramer, the dimeric form 
of GNMT serves as a polycyclic aromatic hydrocarbon binding protein (21). Hence, the 
possibility exists that the activation and induction of GNMT could be achieved by separate 
mechanisms. 
Our laboratory is currently investigating the possible role of gluconeogenesis in 
mediating the induction of GNMT by retinoids because GNMT is found primarily in 
gluconeogenic tissues, which include the liver, kidney, and pancreas (22). Retinoids have 
been shown to exacerbate symptoms of diabetes (23), a condition that is associated with 
elevations in circulating counter regulatory hormones (i.e. glucagon and glucocorticoids) and 
increased gluconeogenesis. Moreover, Xue and Snoswell (24) reported that GNMT activity 
was elevated 65-fold in alloxan-diabetic sheep. Interestingly, glucagon and glucocorticoids 
also play an integral role in the induction of phosphoenolpyruvate carboxykinase (PEPCK), 
the rate-limiting enzyme of gluconeogenesis, which also possesses a retinoid response 
element (25,26). Likewise, GNMT activity is up regulated as a result of phosphorylation by 
cAMP-dependent kinases (20), which have also been shown to increase PEPCK gene 
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expression (25). Therefore, it is possible that a number of signals may play a mediating role 
in retinoid-induced GNMT expression. 
Undoubtedly, a number of potential mechanisms exist that may be responsible for the 
induction of GNMT by retinoids, and the action of retinoid compounds on methyl group 
metabolism may be mediated by other factors. We are currently exploring these research 
areas and the effect of GNMT up-regulation on other aspects of folate and methyl group 
metabolism. These research topics will be important for developing future dietary 
recommendations and the evaluation of other retinoid compounds for clinical use. 
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FIGURE LEGENDS 
FIGURE 1 Interrelationship between methyl group and folate metabolism. Hepatic S-
adenosylmethionine (SAM), a methyl group donor in a number of transmethylation reactions, 
is produced from methionine, via the diet and from the remethylation of homocysteine in a 
B ^ -dependent reaction that utilizes the folate-dependent one-carbon pool as a methyl group 
source (i.e., 5-methyl-tetrahydrofolate, 5-methyl-THF). S-adenosylhomocysteine (SAH), the 
product of SAM-dependent transmethylation reactions, is a potent inhibitor of most 
methyltransferases and thus the ratio of SAM/SAH is an index of transmethylation potential. 
SAM is also an allosteric inhibitor of 5,10-methylene-THF reductase (MTHFR), the enzyme 
that catalyzes the irreversible reduction of 5,10-methylene-THF to 5-methyl-THF. In turn, 5-
methyl-THF is an inhibitor of glycine N-methyltransferase (GNMT), a key protein involved 
in the regulation of transmethylation by controlling the ratio of SAM/SAH. Both of these 
inhibitory relationships are indicated by the dashed arrows. 
FIGURE 2 Administration of 13-cis -retinoic acid (CRA) and all-fra/w-retinoic acid 
(ATRA) to rats for 7 d did not alter their growth rates. Data are means (n=5) ± SEM and 
were compared across treatment groups (f=0.05) at each time point. Following an 
adaptation period, an equal number of rats in both the control and L-methionine-
supplemented (MS, 10 g/kg diet) groups were treated with either vehicle (corn oil), CRA (30 
pmol/kg body weight), or ATRA (30 pmol/kg body weight) daily. For all rats (n=30), mean 
(± SEM) body weights at treatment d=0 and d=7 were 146 ± 3 g and 181 ± 3 g, respectively. 
N.S. indicates not statistically significant. 
FIGURE 3 Administration of 13-cw-retinoic acid (CRA) and all-frow-retinoic acid 
(ATRA) to rats increased the hepatic activity of glycine N-methyltransferase (GNMT) in 
both control and L-methionine-supplemented (MS, 10 g/kg diet) rats. Data are means (n=5) 
± SEM. Bars denoted by different letters are significantly different (P<0.05). All assays 
were performed in triplicate. 
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FIGURE 4 Administration of 13-cw-retinoic acid (CRA) and all-frazro-retinoic acid 
(ATRA) to rats increased the hepatic abundance of glycine N-methyltransferase (GNMT) in 
both control and L-methionine-supplemented (MS, 10 g/kg diet) rats. Data are means (n=5) 
± SEM. Bars denoted by different letters are significantly different (P<0.05). Above the bar 
graph is a representative immunoblot with the relative fold-induction provided below each 
lane. 
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VITAMIN A AND ITS DERIVATIVES INDUCE HEPATIC 
GLYCINE VV-METHYLTRANSFERASE AND HYPOMETHYLATION 
OF DNA IN RATS1 
A paper published in the Journal of Nutrition2 
Matthew J. Rowling3, Mary H. McMullen3, & Kevin L. Schalinske3'4 
Abstract 
Regulation of S-adenosylmethionine (SAM) and the SAM/S-adenosylhomocysteine 
(SAH) ratio by the key cytosolic enzyme glycine iV-methyltransferase (GNMT) is essential in 
optimizing methyl group supply and subsequent functioning of methyltransferase enzymes. 
Therefore, inappropriate activation of GNMT may lead to the loss of methyl groups vital for 
many SAM-dependent transmethylation reactions. Previously, we demonstrated that the 
retinoid derivatives \3-cis- (CRA) and all-frans-retinoic acid (ATRA) mediated both the 
activity of GNMT and its abundance. The present study was conducted to determine if 
vitamin A had a similar ability to up-regulate GNMT as well as to assess the biological 
significance of GNMT modulation by examining both the transmethylation and 
transsulfuration pathways following retinoid treatment. Rats were fed a control (10% casein 
+ 0.3% L-methionine) diet and orally given retinyl palmitate (RP), CRA, ATRA, or vehicle 
daily for 10 d. RP, CRA, and ATRA elevated hepatic GNMT activity 32, 74, and 124% 
respectively, compared to the control group. Moreover, the retinoid-mediated changes in 
GNMT activity were reflected in GNMT abundance (38, 89, and 107% increase for RP-, 
CRA-, and ATRA-treated rats, respectively). In addition, hepatic DNA, a substrate for 
SAM-dependent transmethylation, was hypomethylated (-100%) following ATRA treatment 
compared to the control group. In contrast, the transsulfuration product glutathione was 
unaffected by retinoid treatment. These results provide evidence that (i) vitamin A, like its 
retinoic acid derivatives, can induce enzymatically active GNMT; and (ii) inappropriate 
induction of GNMT can lead to a biologically significant loss of methyl groups and the 
subsequent impairment of essential transmethylation processes. 
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Introduction 
S-adenosylmethionine (SAM)5 is a product of methionine metabolism that serves as a 
donor of methyl groups for transmethylation reactions that are required for the maintenance 
of optimum health and the prevention of disease (1,2). SAM-dependent transmethylation 
reactions include the synthesis of phospholipids, neurotransmitters, and the posttranslational 
modification of nucleic acids and proteins (1,2). Hence, an adequate supply of methyl 
groups provided by the diet in the form of choline and methionine or from the folate-
dependent one-carbon pool must be maintained to ensure these reactions function optimally. 
If an adequate methyl group supply is not maintained, pathological conditions such as 
hepatocarcinogenesis (3,4) and hepatic steatosis (5) may occur. 
Among the end products of SAM-dependent transmethylation reactions is S-
adenosylhomocysteine (SAH), a molecule that is a potent inhibitor of most methyltransferase 
reactions (6). Therefore, control of the SAM/SAH ratio, which is considered an index of 
transmethylation potential (1,2), is a critical aspect of one-carbon metabolism. In order to 
optimize the SAM/SAH ratio, the cytosolic enzyme glycine //-methyltransferase (GNMT) 
functions in conjunction with folate to regulate the methyl group supply. The enzymatic 
activity of GNMT serves to dispose of excess methyl groups through the methylation of 
glycine and subsequent formation sarcosine, a molecule with no known metabolic function 
(Fig. 1). When there is an excess supply of SAM (i.e. methyl groups), SAM allosterically 
inhibits the folate-dependent enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) 
(7,8). This process serves to inhibit the formation of 5-methyltetrahydrofolate (5-methyl-
THF), which in turn, slows the flow of methyl groups from the one-carbon pool into the 
methyl group metabolism pathway and diverts one-carbon units to where they are needed. 
Decreased 5-methyl-THF synthesis also results in elevated GNMT activity and the increased 
catabolism of SAM because GNMT is allosterically inhibited by 5-methyl-THF (9,10). In 
contrast, a compromised supply of SAM releases the inhibition of MTHFR, resulting in 
increased 5-methyl-THF formation and GNMT inhibition. This helps to ensure that methyl 
groups are available for other transmethylation reactions. Therefore, inappropriate activation 
of GNMT during conditions when the methyl group supply is compromised may result in a 
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down-regulation of important transmethylation reactions and subsequent pathological 
conditions. 
Besides transmethylation, activation of GNMT may have important consequences on 
the metabolism of homocysteine, a subsequent product of SAH hydrolysis. After SAH is 
converted to homocysteine, a metabolic branch point exists where homocysteine is either 
remethylated to generate methionine or irreversibly committed to the transsulfuration 
pathway where it can serve as a precursor to biologically significant compounds such as 
cysteine and glutathione (Fig. 1). Currently, no evidence exists that associates activation of 
GNMT and alterations in components of the transsulfuration pathway such as glutathione or 
homocysteine. 
Previously, we showed that methionine catabolism appears to be enhanced in rats 
given the retinoid compound 13-czj,-retinoic acid (CRA) (11). Recently, we reported that a 
potential mechanism for the retinoid-induced increase in methionine/S AM catabolism was 
the activation and induction of hepatic GNMT mediated by both CRA and all-fra/w-retinoic 
acid (ATRA) (12). Based on these findings two obvious questions emerged: 1) does vitamin 
A modulate hepatic GNMT? and 2) does the induction of enzymatically active GNMT by 
retinoids deplete the methyl group supply to the point where hepatic transmethylation and/or 
transsulfuration pathways are compromised? In the present study, we present data that 
indicates that vitamin A does in fact mediate an increase in GNMT, which in turn leads to an 
inability to maintain SAM-dependent methylation of DNA. Furthermore, the increase in 
GNMT abundance by retinoid administration produces GNMT protein that exists primarily 
in its enzymatically active tetrameric state. 
Materials and Methods 
Chemicals and reagents. 
Reagents were obtained from the following: S-adenosyl-L-[/Mef/ÎY/-3H]methionine for 
GNMT activity, New England Nuclear (Boston, MA);, S-adenosyl-L-[mefAy/-3H]methionine 
for DNA methylation assay and ECL Western blotting detection reagents, Amersham 
Pharmacia (Piscataway, NJ); phenylmethylsulfonylflouride and dimethylsulfoxide (DMSO), 
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Calbiochem (La Jolla, CA); disuccinimidyl suberate (DSS), Pierce Chemical (Rockford, IL); 
goat anti-rabbit immunoglobulin G horseradish peroxidase, Southern Biotechnology 
(Birmingham, AL); S-adenosyl-L-methionine and glutathione reductase, Sigma Chemical (St. 
Louis, MO); and Sss I methylase, New England Biolabs (Beverly, MA). GNMT antibodies 
were kindly provided by Conrad Wagner, Vanderbilt University. Retinyl palmitate (RP), 13-
cza-retinoic acid (CRA), and all-/ra>M-retinoic acid (ATRA) were provided courtesy of 
Hoffmann-LaRoche (Nutley, NJ). All other chemicals were of analytical grade. 
Animals and diets. 
All animal experiments were approved and conducted in accordance with Iowa State 
University Laboratory Animal Resources Guidelines. Male Sprague-Dawley (Harlan 
Sprague-Dawley, Indianapolis, IN) rats were housed in plastic cages with a 12-h light:dark 
cycle and given free access to food and water. The control diet was the same as described 
previously (11). After a 7-d acclimation period during which rats were adapted to both the 
diet and oral administration of corn oil, rats were divided into four treatment groups (five rats 
per group) and were orally given either vehicle (com oil, 1 |iL/g body weight), RP, CRA, or 
ATRA on a daily basis for 10 days. Retinoids were prepared in com oil and administered at 
a level of 30 pmol/kg body weight. Although pharmacological in magnitude, this dosage 
was similar to levels used previously (11,12), thus maintaining the continuity of this research 
and allowing comparisons to be drawn. However, current research using more physiological 
levels of retinoids (~1 |xmol/kg body weight) is of significant importance as well. Following 
the 10-d treatment period, rats were anesthetized and portions of liver were removed for 
analysis of GNMT activity, GNMT protein abundance, DNA methylation, and total 
glutathione concentration. 
Measurement of GNMT activity and protein abundance. 
The enzymatic activity of GNMT was measured using the method of Cook and 
Wagner (13) with minor modifications. Portions of liver were homogenized in three volumes 
of ice-cold phosphate buffered (10 mmol/L, pH 7.0) sucrose (0.25 mol/L) containing 
1 mmol/L EDTA, 1 mmol/L sodium azide, and 0.1 mmol/L phenylmethylsulfonylflouride. 
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After centrifugation at 20,000 x g for 30 min, the resulting supernatant was removed and 2-
mercaptoethanol was added to a final concentration of 10 mmol/L. The assay reaction 
mixture (100 pi) contained 0.2 mol/L Tris buffer (pH 9.0), 5 mmol/L dithiothreitol, 2 
mmol/L glycine, and 0.2 mmol/L S-adenosyl-Z,-[meffry/-3H]methionine (47.7 kBq/pmol). The 
reaction was initiated upon the addition of 250 jxg of sample protein and was performed in 
triplicate. GNMT protein abundance was measured using immunoblotting followed by 
chemiluminescence detection as described previously (12). Samples (75 p,g total protein) 
were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
using a 10-20% gradient gel and were electrophoretically transferred to a nitrocellulose 
membrane. For the chemiluminescent detection of GNMT, the membrane was incubated 
with affinity-purified polyclonal GNMT antibody followed by goat anti-rabbit horseradish 
peroxidase. Densitometric analysis was performed using the National Institutes of Health 
Image software. For the determination of total soluble protein concentration in liver extracts, 
a commercial kit (Coomassie Plus, Pierce, Rockford, IL) based on the method of Bradford 
(14) was used with bovine serum albumin as the standard. 
Chemical cross-linking of endogenous GNMT. 
For determining the oligomeric state of GNMT following retinoid treatment, liver 
extracts were incubated with 1.5 mmol/L DSS in DMSO for 30 min at room temperature 
followed by the addition of 6 |iL ethanolamine to terminate the cross-linking reaction (15). 
Samples were subjected to SDS-PAGE followed by immunoblotting and chemiluminescence 
detection as described above. 
DNA methylation. 
To determine whether retinoids induced hypomethylation of hepatic DNA (i.e., 
altered transmethylation), an assay to measure the in vitro incorporation of methyl groups 
into DNA was used (16) with minor modifications. DNA was purified from liver samples 
based on the method of Miller et al. (17) using a commercial kit (Promega, Madison, WI). 
All isolated DNA samples exhibited an A260/280 ratio >1.8 and consisted of DNA > 20 kb as 
determined by agarose gel electrophoresis and ethidium bromide staining. The assay mixture 
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consisted of 1.0 pg DNA, 2.7 |xmol/L S-adenosyl-L-[mer/zyZ3H]methionine (555 GBq/mmol) 
and reaction buffer [10 mmol/L Tris buffer (pH 7.9), 50 mmol/L NaCl, 10 mmol/L EDTA, 1 
mmol/L dithiothreitol] in a total volume of 50 pL. The reaction was initiated upon the 
addition of Sss I methylase (4 units) and was carried out at 30°C for 1 h. After the reaction 
was stopped by heating the samples at 65°C for 20 min, the mixture was applied to Whatman 
DE-81 ion exchange filters fixed on a suction apparatus and washed successively with 20 mL 
500 mmol/L sodium phosphate buffer (pH 7.0), 2 mL 70% ethanol, and 2 mL absolute 
ethanol. The filters were allowed to air dry and subjected to liquid scintillation counting. 
Total liver glutathione. 
For the measurement of total hepatic glutathione concentrations, portions of liver 
were homogenized in 2 volumes of 0.4 mol/L perchloric acid followed by centrifugation at 
10,000 x g for 10 min at 4°C. The resulting supernatant was diluted 100-fold with 125 
mmol/L sodium phosphate buffer (pH 7.5) containing 6.3 mmol/L EDTA and 30 pL was 
used to spectrophometrically measure total glutathione concentrations as described by Tietze 
(18). 
Statistical analysis. 
The means of each treatment group were subjected to a one-way ANOVA (P < 0.05) 
and compared using Fisher's least significant difference procedure (19). For the GNMT 
activity data in Fig. 2 A, the mean of each retinoid-treated group was also individually 
compared to the control group using Dunnet's Test. This second post-hoc test determines 
significant differences between a given treatment group and the control group only, and does 
not compare mean values across treatment groups. For Fig. 3, an association between 
GNMT activity and protein abundance across treatment groups was determined using the 
Pearson Correlation procedure. All statistical analysis was performed using SigmaStat 
(SPSS Inc., Chicago, IL). 
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Results 
Retinoids did not alter the growth rate or relative liver size of rats. 
As we have previously reported (12), all rat groups exhibited similar growth patterns 
(data not shown) and no significant differences in initial (65 ± 1 g) nor final (157 + 2 g) body 
weights were observed across the treatment groups. Likewise, relative liver size was not 
affected by retinoid administration (data not shown). 
Retinoids activate hepatic GNMT. 
The ability of RP, CRA, and ATRA to activate GNMT is shown in Fig. 2 A. Both 
CRA and ATRA significantly elevated the activity of GNMT 74% and 124%, respectively, 
compared to controls. Likewise, RP administration increased GNMT activity (32%), 
however this alteration was not statistically significant (P=0.052). The increase in GNMT 
activity due to RP administration was significant (P=0.020) when the retinoid treatment 
groups were compared to the control group alone (denoted by the asterisk). 
Retinoid compounds, including vitamin A, induce GNMT abundance. 
Fig. 2B illustrates the ability of RP, CRA, and ATRA to significantly induce hepatic 
production of GNMT protein. The bar graph reflects the mean from all experimental 
animals, whereas the immunoblot above is a representative example with the relative fold 
induction located under each lane. All three retinoids, including RP, significantly induced 
GNMT protein abundance. The mean induction of GNMT protein due to retinoid treatment 
ranged from 38 to 107%. Interestingly, it appears that all of the retinoid-induced synthesis of 
GNMT resulted in enzymatically active protein. As shown in Fig. 3, GNMT protein 
abundance was positively correlated with the increase in GNMT activity (r=0.772, P < 
0.001). The ability of retinoids to induce hepatic GNMT in its enzymatically active 
tetrameric state is further illustrated in Fig. 4. Using DSS to cross-link subunits, we 
determined the oligomeric state of GNMT following retinoid treatment. Similar to Fig. 2B, 
all three retinoids induced GNMT monomer (32kD) synthesis {lanes 1-4). The same samples 
were also analyzed following incubation with the cross-linking reagent DSS (lanes 5-8). 
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DSS-treatment of both control and retinoid samples demonstrated that (i) little, if any, of the 
newly synthesized GNMT protein remains as a monomer; and (ii) the majority of the GNMT 
protein was in its tetrameric (128 kD) enzymatically active form. No GNMT was detected in 
the dimeric (64 kD) form (data not shown). 
Retinoid treatment induced hepatic DNA hypomethylation, but failed to alter hepatic 
glutathione levels. 
The effects of RP, CRA, and ATRA on hepatic DNA methylation status are shown in 
Fig. 5. Compared to control rats, hepatic DNA isolated from ATRA-treated rats exhibited a 
greater (~100%) ability to incorporate methyl groups from SAM into hepatic DNA, 
indicating a significant reduction in endogenous methylation status was present following 
retinoid treatment. The mean level of DNA methylation exhibited by RP- and CRA-treated 
rats was not significantly different from control values. To determine whether the disruption 
in the transmethylation pathway due to retinoid administration had a potential effect on 
specific components of the transsulfuration pathway, the hepatic concentration of total 
glutathione was assessed. No significant differences in glutathione levels or the total 
glutathione content of the liver were observed across the treatment groups (data not shown). 
Discussion 
The regulation of the SAM/SAH ratio by GNMT is critical for maintaining an 
optimum supply of methyl groups for transmethylation reactions. Therefore, disruption of 
GNMT function may lead to the unwarranted loss of methyl groups and compromised 
transmethylation reactions. GNMT function has been shown to be altered during diabetic 
conditions (20), ethanol administration (21), and folate deficiency (22); however, the 
physiological consequences of aberrant GNMT function were not explored in these studies. 
Recently, we demonstrated that retinoid compounds have a similar ability to increase GNMT 
activity, an occurrence that was reflected in abundance of the protein (12). In the present 
study, we extending these findings by illustrating that like CRA and ATRA, vitamin A, 
though to a lesser degree, has a similar ability to activate and induce the active tetrameric 
form of GNMT, as was illustrated in our cross-linking studies. Because vitamin A needs to 
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be converted to its active retinoic acid derivatives before it can function physiologically, the 
reduced sensitivity of methyl group metabolism to retinyl palmitate is not surprising. 
Determining the mechanism by which retinoids exert their actions on GNMT remains 
a major focus of ongoing research in our laboratory. It has been documented that GNMT 
activity is regulated at the posttranslational level by phosphorylation of the subunits that 
constitute the active GNMT tetramer (10) and by allosteric inhibition by folate coenzymes 
(9). Therefore, we certainly have not ruled such posttranslational modification out as a 
potential mechanism for retinoid-mediated GNMT up-regulation. However, we are intrigued 
by the findings of the present study illustrating that GNMT activity was directly proportional 
to abundance of the protein following treatment with all three retinoids. These findings 
clearly indicate that vitamin A compounds modulate GNMT activity at the 
transcriptional/translational level however, because the promoter region for GNMT does not 
contain a retinoid response element, retinoid-mediated GNMT induction may be due to 
increased stability of GNMT protein and/or messenger RNA. We are currently exploring 
these research areas as well as the possibility that the effect of retinoids on GNMT is 
mediated by other factors such as gluconeogenesis. GNMT is found primarily in 
gluconeogenic tissues and is up-regulated during conditions consistent with gluconeogenesis 
such as diabetes (20). Moreover, retinoids, along with hormones such as glucocorticoids and 
glucagon, are required for the expression of phosphoenolpyruvate carboxykinase (PEPCK) 
(23), the rate-limiting enzyme for gluconeogenesis. Hence, it seems logical that the 
stimulation of gluconeogenesis could play a role in mediating the effects of retinoids on 
GNMT. Peng and Evenson (24) showed that alleviation of methionine toxicity by retinol 
pretreatment was prevented after rats were adrenalectomized, therefore; glucocorticoids may 
be required for vitamin A to exert its actions on the catabolism of methionine. 
Our findings also indicate that up-regulation of GNMT results in aberrant methyl 
group metabolism. GNMT constitutes 1-3% of cytosolic protein in the liver (6), therefore; 
this finding is not surprising. The degree of GNMT activation by retinoid compounds 
appears to be directly related to their ability to compromise other SAM-dependent 
transmethylation reactions. This is supported by the fact that ATRA, the most biologically 
active of the retinoid compounds utilized in the present study was the most effective in 
64 
producing hypomethylated DNA. Such findings clearly indicate that retinoid administration 
may produce a functional methyl group deficiency. The potential for retinoid treatment to 
compromise SAM-dependent transmethylation is also supported by the observation that rats 
treated with ATRA exhibited a significant reduction in creatinine synthesis (McMullen, 
M.H., Rowling, M.J., Ozias, M.K. & Schalinske, K.L., unpublished observations). Because 
creatinine synthesis is one of the major depots for methyl groups from SAM, this further 
stresses the physiological significance of retinoid-mediated alterations in GNMT. Retinoid-
mediated hypomethylation of DNA has significant implications due to the link between DNA 
methylation and a number of important processes, such as gene expression and development 
(25-28). 
During the course of these and other studies, it was evident that rats within a 
treatment group exhibited a significant degree of variability with respect to methylation 
status of DNA. Our treatment period (10 d) was fairly rapid compared to other reports on 
hypomethylation of DNA that typically employ treatment periods ranging from 1-4 weeks 
using methyl- and/or folate-deficient diets (16,28,29). We are currently conducting time 
course studies examining retinoid-mediated changes in methyl group metabolism, which we 
expect will aid in explaining this variability. Although only ATRA-treated rats exhibited a 
statistically significant increase in hypomethylation of DNA, it is important to note that we 
found a positive correlation (r=0.667, P=0.0013) between GNMT activity and DNA 
methylation (data not shown). In contrast to SAM-dependent transmethylation, retinoid-
treated rats failed to exhibit significant changes in hepatic concentrations of total glutathione, 
indicating that the transsulfuration pathway remains partially intact, at least with respect to 
maintaining normal glutathione levels. Earlier work demonstrated that increased methionine 
catabolism by dietary CRA resulted in a significant increase in hepatic taurine concentrations 
that was achieved, in part, at the expense of reduced inorganic sulfate excretion and 
diminished hepatic glutathione levels (5,11). 
In summary, it is clear that retinoid compounds, as vitamin A or as a retinoic acid 
derivative, represent a potent group of compounds capable of perturbing methyl group 
metabolism. Although the doses we utilized in these studies are pharmacological in 
magnitude, our preliminary work suggests that modulation of GNMT can be achieved using 
65 
more physiological levels (~1 pmol/kg body weight) as well (data not shown). Thus, future 
work is being directed at this issue by performing both dose-response and time-course 
studies. Moreover, the potential impact of retinoid administration on perturbation of the 
folate-dependent one-carbon pool and subsequent remethylation of homocysteine is a 
component of these future studies. This research direction is supported by previous studies 
demonstrating that vitamin A status influences the one-carbon pool (30,31) as well as a 
recent report that plasma homocysteine levels were elevated in patients receiving CRA 
therapy (32). 
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FIGURE LEGENDS 
FIGURE 1 Methyl group metabolism. Methyl groups, as methionine, can be converted to 
SAM and function as a substrate in numerous SAM-dependent transmethylation reactions. 
GNMT regulates the transmethylation potential by controlling the SAM/SAH ratio. 
Following the hydrolysis of S AH, a branch point exists where homocysteine can either be 
remethylated by 5-methyl-THF to generate methionine, or used for the synthesis of 
biologically significant metabolites such as cysteine and glutathione via the transsulfuration 
pathway. Abbreviations used: GNMT; glycine JV-methyltransferase, S AH; S-
adenosylhomocysteine, SAM; S-adenosylmethionine, THF; tetrahydrofolate. 
FIGURE 2 Retinoid administration activated hepatic GNMT in rats. Panel A, elevation 
of hepatic GNMT activity mediated by RP, CRA, and ATRA. All assays were performed in 
triplicate. Panel B, induction of GNMT protein mediated by RP, CRA, and ATRA. The 
immunoblot above the bar graph (Fig. 2B) is a representative example with the relative fold 
induction located below each lane. Data are means + SEM, n- 5. Bars without a common 
letter are significantly different (P < 0.05). Bars with an asterisk are significantly different (P 
< 0.05) when compared to the control group alone. 
FIGURE 3 Correlation between GNMT activity and abundance across retinoid treatment 
groups. Symbols represent individual values within each group. Results of a Pearson 
correlation test are indicated by the solid line (r = 0.772, P = 0.00007). 
FIGURE 4 The enzymatically active tetrameric form of GNMT was mediated by retinoid 
treatment. Cytosolic extracts were subjected to the cross-linking reagent disuccinimidyl 
suberate (DSS) prior to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting using a polyclonal GNMT antibody. As indicated by the 
arrows, bands at -32 kD represent the monomeric form of GNMT, whereas the tetrameric 
form is shown at a molecular weight of ~128 kD monomer. No immunoreactive bands were 
discernible at 64 kD, representing the dimeric form of the protein (data not shown). Hepatic 
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extracts from control, RP-, CRA-, and ATRA-treated rats in the absence of DSS treatment 
are shown in lanes 1-4, respectively, whereas the same samples subjected to DSS cross-
linking prior to SDS-PAGE are shown in lanes 5-8. 
FIGURE 5 Administration of ATRA to rats resulted in hepatic DNA hypomethylation. In 
this assay, the ability to serve as an acceptor for methyl groups is inversely proportional to 
endogenous methylation status. Data are means + SEM, n = 5. Bars without a common 
letter are significantly different (P < 0.05). 
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RETINOIC ACID AND GLUCOCORTICOID TREATMENT INDUCE 
HEPATIC GLYCINE N-METHYLTRANSFERASE AND LOWER 
PLASMA HOMOCYSTEINE CONCENTRATIONS IN RATS AND RAT 
HEPATOMA CELLS1 
A paper published in the Journal of Nutrition2,3 
Matthew J. Rowling4 and Kevin L. Schalinske4,5 
Abstract 
Perturbation of folate and methyl group metabolism is associated with a number of 
pathological conditions, including cardiovascular disease and neoplastic development. 
Glycine N-methyltransferase (GNMT) is a key protein that functions to regulate the supply 
and utilization of methyl groups for S-adenosylmethionine (SAM)-dependent 
transmethylation reactions. Factors or conditions that have the ability to regulate GNMT and 
the generation of homocysteine, a product of transmethylation, have significant implications 
in the potential perturbation of methyl group metabolism. We have shown that retinoid 
compounds induce active hepatic GNMT, resulting in compromised transmethylation 
processes. Because retinoids can stimulate gluconeogenesis, a condition known to alter 
methyl group and homocysteine metabolism, the current study was undertaken to determine 
the relationship between all-Zrara-retinoic acid (RA) and gluconeogenic hormones on these 
metabolic pathways. It was found that intact adrenal function was not required for RA to 
induce and activate hepatic GNMT; however, treatment of rats with dexamethasone (DEX) 
was as effective as RA to induce GNMT in rat liver. The marked increase in plasma total 
homocysteine levels observed in adrenalectomized rats was reduced to normal levels by 
treatment with either RA or DEX, indicating that the transsulfuration and/or remethylation 
pathways may be enhanced. Moreover, co-administration of RA and DEX resulted in an 
additive effect on GNMT induction. Similar findings were also observed in a rat hepatoma 
cell culture model using H4IIE cells. Taken together, these results demonstrate that both RA 
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and DEX independently induce GNMT, thereby having significant implications for the 
potential interaction of retinoid administration with diabetes. 
Key words: • glycine N-methyltransferase • methyl groups • homocysteine • retinoic acid • 
dexamethasone 
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Introduction 
Glycine iV-methyltransferase (GNMT)6 is a key cytosolic protein in the regulation of 
methyl group and folate metabolism that controls the supply of available methyl groups for 
S-adenosylmethionine (SAM)-dependent transmethylation reactions (1). By disposing of 
excess methyl groups as sarcosine, a molecule that has no known physiological function, 
GNMT controls the SAM/S-adenosylhomocysteine (SAH) ratio (2), which is considered an 
important index of transmethylation potential because of the ability of SAH to inhibit the 
majority of SAM-dependent transmethylation reactions (3). Interestingly, GNMT does not 
appear to be among the methyltransferases that are sensitive to such SAH inhibition (4). 
Over 100 critical transmethylation reactions readily occur in the mammalian cell, including 
the methylation of DNA and methylation reactions required during the synthesis of vital 
biological compounds such as neurotransmitters, phospholipids, and nucleic acids (3,4). 
Therefore, maintaining an optimum supply of activated methyl groups (i.e. SAM) is critical 
for the proper functioning of a vast number of enzymes that catalyze methyl transfer 
reactions that are essential for the prevention of disease. 
A number of interactions exist between the methyl group- and folate-dependent one-
carbon metabolism pathways to ensure that methyl groups are readily available for use in 
SAM-dependent transmethylation reactions (Fig. 1). SAM serves as an inhibitory ligand for 
5,10-methylenetetrahydrofolate reductase (MTHFR) (5), therefore; an elevated intracellular 
supply of SAM decreases the synthesis of 5-methyltetrahydrofolate (5-methyl-THF). 
Additionally, 5-methyl-THF is an allosteric inhibitor of GNMT (6,7), hence; an elevated 
concentration of SAM indirectly leads to its own catabolism by increasing GNMT activity 
through the inhibition of 5-methyl-THF synthesis. GNMT can then dispose of the excess 
methyl groups supplied by SAM as sarcosine. In contrast, decreased SAM levels facilitate 
the production of 5-methyl-THF and subsequent folate-dependent remethylation of 
homocysteine by 5-methyl-THF to regenerate methionine. The rise in 5-methyl-THF 
concentrations also inhibits GNMT activity, which in turn conserves the supply of activated 
methyl groups for important SAM-dependent transmethylation reactions. Following 
transmethylation, SAH is hydrolyzed to generate homocysteine and adenosine. 
Homocysteine can then be remethylated by either methionine synthase (MS) or 
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betainehomocysteine methyltransferase (BHMT), processes that require 5-methyl-THF or 
betaine, respectively, or committed to the transsudation pathway by cystathionine /?-
synthase (C/?S) for its catabolism. Besides the removal of homocysteine, transsudation is 
essential for the production of important molecules such as cysteine and glutathione. 
Because of the central role of GNMT in the regulation of methyl group and folate 
metabolism, a disturbance of GNMT function may alter the synthesis of such compounds and 
thus result in a number of pathological conditions (8-10). 
A number of nutritional components and hormones have recently been identified as 
factors that modulate the expression of key enzymes that play critical roles in methyl group 
and folate metabolism. We showed that the administration of retinoid compounds activated 
and induced GNMT expression in rats, which resulted in compromised methylation of 
hepatic DNA (11). Others have shown in animal and cell culture studies that conditions 
associated with a lack of insulin (e.g. diabetes) and administration of the counterregulatory 
hormones, glucagon and glucocorticoids increased the expression of critical enzymes central 
to methyl group and folate metabolism, including C/?S and MTHFR (12-14), which are 
required for the removal of homocysteine. Moreover, Xue and Snoswell (15) discovered that 
GNMT activity was elevated 65-fold in diabetic sheep. Although it has not been determined 
whether gluconeogenic conditions prevalent during uncontrolled diabetes increase the 
expression of GNMT, it is known that GNMT resides primarily in the liver, kidney, and 
pancreas (16), organs that play significant roles during gluconeogenesis. Therefore, it is 
conceivable that GNMT can be regulated by gluconeogenic factors such as increased 
counterregulatory hormone levels, an occurrence that in turn, may affect other critical aspects 
of methyl group and folate metabolism such as the metabolism of homocysteine. 
Hence, we postulated that the ability of retinoids to modulate GNMT was due to an 
association between retinoids and gluconeogenesis. All-Zrazw-retinoic acid has been shown 
to increase the gene expression of phosphoenolpyruvate carboxykinase (PEPCK) (17,18), the 
rate-limiting enzyme of gluconeogenesis. However, unlike PEPCK, no retinoic acid 
response element has been found in the promoter region for GNMT. Thus, it seems likely 
that the affect of retinoids on GNMT expression is secondary to other events, such as 
elevated counterregulatory hormone levels. Peng and Evenson (19-21) showed that 
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methionine toxicity was alleviated in rats pretreated with retinol, an occurrence that was 
reversed when rats were adrenalectomized, indicating that the adrenal glands could play a 
key mediating role in the induction of GNMT by retinoid compounds. In the present study, 
we examined the role of the adrenals and dexamethasone (DEX) in the regulation of GNMT, 
alone and in combination with RA using both an in vivo rat model and cell culture studies. 
Furthermore, we determined whether the modulation of GNMT due to the various treatments 
was associated with alterations of plasma homocysteine levels. 
Materials and Methods 
Chemicals 
Materials were obtained form the following sources: tissue culture reagents, Life 
Technologies, Inc.(Rockville, MD); S-adenosyl-L-[mefAy/-3H]methionine, PerkinElmer 
(Boston, MA); goat anti-rabbit immunoglobulin G horseradish peroxidase, Southern 
Biotechnology (Birmingham, AL); ECL Western blotting detection reagents, Amersham 
Pharmacia (Piscataway, NJ); S-adenosyl-L-methionine and dexamethasone, Sigma Chemical 
(St. Louis, MO); and protease inhibitors and RA, Calbiochem (La Jolla, CA). All other 
reagents were of analytical grade. 
Animal experiments 
All animal experiments were approved by and conducted in accordance with Iowa 
State University Laboratory Animal Resources Guidelines. Adrenalectomized (ADX) and 
sham-operated male Sprague Dawley (Harlan Sprague Dawley, Indianapolis, IN) rats (125-
149 g) were housed in plastic cages and given free access to food and water in a room with a 
12-h light: dark cycle. ADX rats received saline (10 g/LNaCl) as drinking water. The 
composition of the control diet was the same as previously described (22) except the AIN-
93G formulation of vitamin and mineral mix was utilized. After rats were acclimated to both 
the control diet and oral administration of com oil, they were randomly assigned to various 
treatment groups (five rats per group) and given a daily oral dose of either vehicle (corn oil) 
or vehicle containing RA (30 [xmol/kg BW). Although this represents a pharmacological 
dose of RA and we have shown that levels as low as 5 pmol/kg BW effectively elevated 
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GNMT activity, the maximal saturating effect of RA on GNMT induction was achieved 
using the higher concentrations1. For glucocorticoid studies, rats were given a daily 
intraperitoneal injection of DEX (1 mg/kg BW) that was dissolved in a vehicle containing 
propylene glycol: absolute ethanol: glacial acetic acid: ascorbic acid (95:5:0.6:0.01, 
v/v/v/w). In preliminary studies, we found that this level of DEX administration was equally 
effective as higher doses (i.e., saturating) and allowed maintenance of normal body weight. 
After a 5-7 d treatment period with RA and/or DEX, rats were anesthetized with a 
intraperitoneal injection of ketamine: xylazine (90:10 mg/kg BW) and blood samples were 
collected via cardiac puncture in heparinized syringes, centrifuged at 4,000 X g for 8 min, 
and stored at -20°C until analysis. Liver and pancreatic tissue samples were rapidly removed 
and homogenized in ice-cold buffer containing: 10 mmol/L sodium phosphate (pH 7.0), 0.25 
mol/L sucrose, 1 mmol/L EDTA, 1 mmol/LM sodium azide, 0.1 mmol/L 
phenylmethylsulfonyl fluoride. Following centrifugation at 20,000 x g for 30 min, p-
mercaptoethanol was added to the resulting supernatants to a final concentration of 10 
mmol/L and they were stored at -70°C for subsequent analysis of GNMT activity and 
abundance as previously described (11,23). 
Cell culture 
Rat hepatoma H4IIE cells (American Type Culture Collection, Manassas, VA) were 
grown in 150-cm2 flasks to 70-75% confluence under 5% CO2 in a humidified incubator at 
37°C in Dulbecco's modified Eagles medium containing 100 mL/L fetal bovine serum, 
penicillin (100,000 units/L), and streptomycin (100 mg/L). Cells were given fresh media 
immediately prior to treatments. Cells were either treated alone, or with various 
combinations of DEX (0.1 fimol/L), dibutyryl-adenosine-3,5-cyclic monophosphate 
(Bt2cAMP, 0.5 mmol/L ), glucagon (0.5 jumol/L) and/or RA (10 nmol/L). Preliminary dose-
response studies established these levels as optimal for modulating methyl group metabolism. 
Following a 72- h incubation period in the presence of the various treatment reagents, cells 
were detached with 2.5 g/L trypsin/1 mmol/L EDTA, washed twice in Hanks' balanced salt 
solution, and lysed on ice in a buffer containing: 10 mmol/L Hepes (pH 7.4), 10 mmol/L 
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sodium pyrophosphate, 50 mmol/L sodium fluoride, 50 mmol/L ^-glycerophosphate, 5 
mmol/L EDTA, 1 mmol/L sodium orthovanadate, 2 mmol/L benzamidine, 100 mg/L 
leupeptin and pepstatin, 250 mg/L soybean trypsin inhibitor, 0.2 mmol/L 
phenylmethylsulfonylflouride, 24 mg/L /»-nitroguanidinobenzoate, and 5 mL/L Nonidet P-40. 
Lysates were centrifuged at 16,000 x g for 8 min after which supernatants were removed 
and stored at -70°C for subsequent analysis of GNMT protein abundance. 
Measurement of GNMT activity 
The enzymatic activity of GNMT was determined in tissue supernatants as described 
by Cook and Wagner (1984) with minor modifications (11). The assay reaction mixture (100 
}o.L) consisted of 200 mmol/L Tris buffer (pH 9.0), 5 mmol/L dithiothreitol, 2 mmol/L 
glycine, and 2 mmol/L [methyl-3H/SAM (47.7 kBq/^imol). The reaction was initiated with 
250 p.g cytosolic protein and incubation of the assay mixture was carried out at 25°C for 30 
min. The reaction was terminated by the addition of trichloroacetic acid and activated 
charcoal was used to remove unreacted radiolabeled SAM by centrifugation. An aliquot of 
the resulting supernatant containing the radiolabeled product was removed for liquid 
scintillation counting and GNMT activity was expressed as pmoles sarcosine formed/ 
(min-mg protein). All GNMT assays were performed in triplicate. 
Analysis of GNMT protein abundance 
The abundance of GNMT protein in tissue and cell culture extracts was determined 
using immunoblotting techniques as previously described (11,23,25). Briefly, a 10-20% 
gradient gel was cast for SDS-polyacrylamide gel electrophoresis for determination of the 
abundance of the 32 kDa monomer subunit of GNMT, which functions enzymatically in its 
homotetrameric form. Following separation, proteins were electrophoretically transferred to 
a nitrocellulose membrane, followed by incubation with either an affinity-purified polyclonal 
GNMT antibody (kindly provided by C. Wagner, Vanderbilt University) or a monoclonal 
GNMT antibody (26) that recognizes a specific peptide sequence within the protein (kindly 
provided by Y-M.A. Chen, National Yang-Ming University, Taipei, Taiwan). For either 
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primary antibody, blots were incubated overnight at 4°C followed by a 1-h incubation at 
room temperature with goat anti-rabbit horseradish peroxidase secondary antibody. GNMT 
abundance was assessed by chemiluminescence detection and, following multiple exposures 
to Kodak X-Omat AR film, densitometric analysis was performed using SigmaGel Software 
(SPSS, Chicago, II). For both enzyme activity measurements and Western blot analysis, total 
soluble protein concentration in liver and cell extracts was determined by the method of 
Bradford (27) using a commercial kit (Coomassie Plus, Pierce Chemical, Rockford, IL) and 
bovine serum albumin as a standard. 
Determination of plasma homocysteine concentrations 
Total (free + protein bound) homocysteine concentrations were determined using 
high-performance liquid chromatography with fluorescence detection (28). Plasma samples 
were derivatized with 7-flouro-2-oxa-1,3-diazole-4-sulfonate and a 100 ^L sample 
containing the thiol adducts was injected onto a pBondapak Cig Radial-Pak column (Waters 
Corporation, Milford, MA) using a mobile phase consisting of 40 mL/L acetonitrile in 0.1 
mol/L potassium phosphate (pH 2.1) buffer, ^-acetylcysteine was added to plasma samples 
prior to derivatization as an internal standard. 
Statistical analysis 
The mean values from each treatment group were subjected to a one- or two-way 
ANOVA (29). If the ANOVA was significant (P < 0.05), the means were compared using 
Fisher's least significant difference procedure. All statistical analysis was performed using 
SigmaStat software (SPSS, Chicago, IL). 
Results 
Intact adrenal function was not required for the induction of hepatic GNMT by RA 
As shown in Fig. 2, the activity and abundance of GNMT was elevated following 
administration of RA to adrenalectomized rats. As we have shown previously, RA increased 
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both the activity (Fig. 2A) and abundance (Fig. 2B) of hepatic GNMT ~2.0-fold in sham-
operated control rats. The immunoblot above the bar graph in Fig. IB is a representative 
sample from each treatment group with the relative fold-induction indicated under each lane. 
Removal of the adrenal glands did not alter the basal activity or the abundance of GNMT; 
administration of RA was equally effective at elevating GNMT activity (1.9-fold) and 
abundance (2.0-fold) in ADX rats compared to their respective untreated controls. These 
findings indicate that RA regulates methyl group metabolism in a manner that is independent 
of adrenal function. 
Hepatic GNMT was activated and induced by both RA and glucocorticoid treatment 
Although it did not appear that adrenal function was required for GNMT regulation 
by RA, a primary objective was to determine whether glucocorticoids, alone or in 
combination with RA, could also stimulate GNMT expression (Fig. 3). For sham-operated 
rats, treatment with DEX increased the activity of GNMT in a manner similar to that 
exhibited by RA-treated rats (1.6- and 1.9-fold, respectively). Similar results were observed 
following treatment of ADX rats with RA and DEX; hepatic GNMT activity was elevated 
2.0- and 2.4-fold, respectively. Moreover, when administered together, RA and DEX clearly 
appeared to have an additive effect on activating GNMT in both sham-operated (2.6-fold) 
and ADX (3.6-fold) rats compared to control values. The activation of hepatic GNMT by 
RA and DEX, alone or in combination, was reflected in the abundance of the protein, as 
shown by the Western blot in Fig. 4A. In contrast, pancreatic GNMT protein abundance was 
not responsive to either RA, as we have previously reported (25), or DEX treatment in sham-
operated (Fig. 42?) or ADX rats (data not shown). The activity of GNMT in the pancreas 
also remained constant regardless of RA or DEX administration in both sham-operated and 
ADX rats (data not shown). These results indicate that in addition to RA, the glucocorticoid 
DEX was equally effective at regulating the expression of GNMT in both sham-operated and 
ADX rats in a tissue-specific manner; the additive effect of co-administration of RA and 
DEX suggest that the basis for their action, at least in part, is mechanistically distinct from 
each other. 
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Homocysteine levels were reduced by RA and DEX treatment of adrenalectomized rats 
Recent work has shown that a diabetic state (i.e., the absence of insulin) or an 
equivalent elevation in circulating counter-regulatory hormones (i.e., glucagon and/or 
glucocorticoids) leads to a decrease in plasma homocysteine concentrations in rats due to an 
increase in homocysteine catabolism through the transsulfuration pathway (12-14). We 
explored the possibility that RA had a similar ability to reduce homocysteine levels, 
indicating that the excessive production of homocysteine due to GNMT induction resulted in 
an increase in its metabolism. Fig. 5 demonstrates that plasma homocysteine levels were 
elevated greater than 2-fold as a result of adrenalectomy. Moreover, both RA and DEX were 
effective in reducing homocysteine levels (41 and 74%, respectively) in ADX rats; no further 
decrease was observed when RA and DEX were provided simultaneously. In contrast, 
homocysteine concentrations were not significantly reduced by either RA and/or DEX 
treatment in sham-operated rats. 
Induction of GNMT in rat hepatoma cells 
To assess the ability of RA and hormones to directly induce expression of GNMT 
protein, we utilized a cell culture system consisting of a rat hepatoma cell line. GNMT is not 
expressed to a significant degree in most cell lines, including human HepG2 cells; however, 
in preliminary experiments we found that H4IIE cells did express discernible levels of 
GNMT and the regulation of GNMT in this cell line was sensitive to factors shown to be 
effective in vivo. As shown in Fig. 6, GNMT abundance in H4IIE cells was subject to 
regulation by RA (lanes 1-4). This regulation of GNMT protein abundance by RA in H4IIE 
cells was similar to what was observed in rat liver (lanes 5-8). For comparative purposes, 
Fig. 6 also demonstrates that the level of expressed GNMT protein, relative to a given 
amount of total cellular protein, was significantly less in H4IIE cells compared to rat liver. 
Further comparison of GNMT regulation in H4IIE cells to rat liver is shown in Fig. 7. 
Similar to the rat liver data shown earlier in Fig. 3, RA and DEX treatment of H4IIE cells 
increased GNMT abundance 2.6- and 3.6-fold, respectively. Moreover, co-administration 
with both compounds resulted in an additive 4.8-fold stimulation of GNMT expression. 
These results using a cell culture model demonstrate that both RA and DEX regulate methyl 
group metabolism directly, in the absence of other physiological factors. Moreover, 
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pretreatment of H4IIE cells with actinomycin D abolished the ability of both RA and DEX to 
increase GNMT abundance, indicating transcriptional mechanisms were involved (data not 
shown). 
In addition to DEX, a number of other components have also been shown to play a 
potential role in the regulation of GNMT, methyl group and homocysteine metabolism. 
Thus, H4IIE cells were treated with various combinations of RA, DEX, BtzcAMP, and 
glucagon (Fig. 8). As shown earlier in Fig. 7, the immunoblot shown in Fig. SA 
demonstrates that exposure of H4IIE cells to RA or DEX (lanes 2 and 3, respectively, 
compared to lane 1) resulted in the induction of GNMT protein (2.1 - and 1.8-fold, 
respectively) and cells incubated with both RA and DEX (lane 6) exhibited an elevation of 
GNMT protein abundance that appeared to be additive (4.8-fold increase). In contrast, 
incubation with Bt2cAMP alone did not induce GNMT compared to controls (compare lanes 
4 and lane 1). Moreover, the addition of Bt^cAMP appeared to attenuate GNMT induction in 
cell cultures treated with RA and/or DEX (compare lanes 5 and 2; lanes 7 and 3; lanes 8 and 
6). As shown in Fig. 8B, experiments with glucagon-treated H4IIE cells (lane 3) resulted in 
similar findings as Bt^cAMP (lane 4) in that no induction was discernible compared to 
untreated cells (lane 1), in contrast to the 4.5-fold increase exhibited by cells treated with 
both RA and DEX (lane 2). 
Discussion 
GNMT regulates the supply of methyl groups available for transmethylation reactions 
through its control of the SAM/SAH ratio (1). Because GNMT constitutes 1-3% of total 
cytosolic protein in the liver (2), and its enzymatic activity is strongly inhibited by folate 
coenzymes (6,7), the physiological role of GNMT appears to be of major significance. A 
number of conditions are known to produce alterations in GNMT function and subsequent 
methyl group metabolism including various nutritional and/or metabolic disorders such as 
folate deficiency (30), methyl group excess (31,32), ethanol administration (33), diabetes 
(15), genetic disorders (34,35) as well as gender (25), and age (36). Because an adequate 
supply of methyl groups must be maintained to ensure that important SAM-dependent 
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transmethylation reactions (e.g. DNA methylation) can readily occur, a perturbation of 
GNMT may lead to a number of pathological conditions, such as carcinogenesis. 
Here, and in our earlier work (11,23,25), we showed that retinoid compound represent 
a family of compounds that have the ability to modulate GNMT and methyl group 
metabolism. In addition, the results of the present study clearly indicate that GNMT is 
modulated by RA at the transcriptional/translational level in H4IIE rat hepatoma cells. This 
is a novel regulatory aspect because previous work in tissue culture has focused on 
posttranslational modification of GNMT via phosphorylation or allosteric binding by 5-
methyl-THF as mechanisms by which GNMT can be modulated (6,7). Although we 
certainly have not ruled such posttranslational modification of GNMT out as an explanation 
of our findings, a more likely scenario for the retinoid-mediated increase of GNMT protein 
abundance observed in the present study may be increased stability of the protein and/or 
GNMTmRNA. 
In contrast to previous work that showed adrenal function was required to mediate the 
catabolic events of vitamin A compounds on methionine metabolism (19-21), our results 
indicate that RA exerted its effects on GNMT independent of intact adrenal function and 
increased secretion of glucocorticoids. We demonstrated for the first time, however, that 
treatment with exogenous glucocorticoids (DEX) was as effective as RA in inducing active 
GNMT in hepatic tissue of both intact and ADX rats. Furthermore, when DEX and RA were 
co-administered to rats and H4IIE cells, the induction of active GNMT appeared to be 
additive, suggesting that these compounds may exert their actions by two distinct cellular 
mechanisms. In contrast, it was clear that GNMT was not sensitive to treatment with 
glucagon or Bt%cAMP treatment. Because no response elements for RA, glucocorticoids, or 
cAMP are known to exist in the promoter region of GNMT, it is likely that the effects of 
these compounds on GNMT is secondary to other effects. 
Based on earlier studies that showed that the catabolism of methionine was enhanced 
in rats pre-treated with retinol (21), we hypothesized that increased production of methionine 
degradation products (i.e. homocysteine) would occur as a result of GNMT activation. 
However, our results do not indicate that GNMT induction by either RA or DEX treatment is 
consistent with increased homocysteine concentrations. In fact, both RA and DEX 
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treatments essentially normalized elevated homocysteine concentrations present in ADX rats, 
indicating that the catabolism of homocysteine through the transsulfuration pathway may 
have been enhanced following treatment with these compounds. This is consistent with 
earlier findings that showed diabetic conditions (i.e. gluconeogenesis) and treatment with 
glucocorticoids facilitated the removal of homocysteine through the transsulfuration pathway 
(12,14,15). Thus, our findings with RA-treated rats indicate that in addition to 
glucocorticoids (14), retinoids may represent a group of compounds that increase the 
expression of enzymes central to the transsulfuration pathway. We are intrigued by the fact 
that homocysteine levels were elevated in ADX rats before treatment with RA and/or DEX 
despite GNMT activity remaining unaltered compared to the intact control animals. The 
latter indicates that the basal rate of methionine catabolism may not be dependent on adrenal 
function. Likewise, the induction of active GNMT by RA and DEX was similar in both 
intact and ADX rats. Therefore, it is possible the increased homocysteine levels in ADX rats 
resulted from the down-regulation of the remethylation process, which may be related to 
decreased glucocorticoid synthesis by the adrenals. This is supported by previous studies 
examining the hormonal regulation of MTHFR that showed glucocorticoids enhance its 
enzymatic activity (37). Recent data in our laboratory indicates that retinoids may have a 
similar ability to enhance the folate-dependent remethylation of homocysteine in intact rats 
by increasing methionine synthase (MS) activity (38). In the present study, administration of 
RA and/or DEX did not reduce plasma homocysteine levels in intact rats; however, we have 
consistently found that younger rats treated with RA for longer time periods (8-10 d) had a 
significant (~50%) reduction in the concentration of plasma homocysteine (38). 
A number of other possible explanations for the reduction of homocysteine levels 
must be considered in addition to enhanced transsulfuration. Although it is logical to 
presume that the increased catabolism of methionine following GNMT induction would 
produce elevated homocysteine concentrations, the subsequent down-regulation of other 
SAM-dependent transmethylation reactions may be responsible for reducing homocysteine 
levels. Previous work in our laboratory has demonstrated retinoid-mediated GNMT 
induction is consistent with the perturbation of a number of SAM-dependent 
transmethylation reactions, including the methylation of DNA and the synthesis of creatinine 
88 
(25), and may be indirectly responsible for the development hepatic steatosis (39), 
presumably due to decreased phosphatidylcholine (PC) synthesis (40). Interestingly, a recent 
study showed that phosphatidylethanolamine N-methyltransferase, the SAM-dependent 
enzyme required for PC synthesis, plays a major role in the regulation of homocysteine 
metabolism (41). Creatinine and PC synthesis are SAM-dependent transmethylation 
reactions that require a significant supply of methyl groups, therefore; it seems plausible that 
if either reaction were perturbed, a reduction of plasma homocysteine concentrations would 
occur. 
We have found an association between glucocorticoid and retinoid administration 
with alterations of methyl group/homocysteine metabolism. Thus, our findings have 
significant implications in a number of different areas related to health and disease. Our 
findings add to the increasing evidence that implicates gluconeogenic conditions, such as 
uncontrolled diabetes, in the alteration of methyl group and homocysteine metabolism. 
Diabetes and administration of glucocorticoids and/or glucagon are known to modulate 
homocysteine metabolism and the activity of GNMT (12-15). Similarly, the results in the 
present study indicate that administration of RA can modulate methyl group metabolism, 
which may be related to retinoid-mediated gluconeogenic conditions. This is supported by 
preliminary data in our lab that showed diabetic rats were significantly more sensitive to 
increases in blood glucose levels and GNMT induction by treatment with RA (Rowling, M. 
J. and Schalinske, K. L., unpublished data). These findings suggest that diabetic individuals 
receiving retinoid therapy for conditions such as cystic acne and various forms of leukemia 
may require alternative therapies for their conditions or need to be closely monitored. The 
sensitivity of humans to perturbation of methyl group metabolism by retinoid compounds 
may also have significance with respect to individuals carrying common mutations of key 
enzymes involved in folate, and methyl group/homocysteine metabolism, such as C0S and 
MTHFR polymorphisms. With the increasing prevalence of retinoids being prescribed for 
therapeutic purposes (-800,000 new cases each year) (42), the need for monitoring these 
individuals may become more apparent. 
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FIGURE LEGENDS 
FIGURE 1 Folate, methyl group, and homocysteine metabolism. Glycine N-
methyltransferase (GNMT) regulates the ratio of S-adenosylmethionine (SAM) to S-
adenosylhomocysteine (SAH), thereby optimizing transmethylation reactions (X —> X-CH3), 
such as the methylation of DNA, RNA, proteins, and phospholipids. SAM is an allosteric 
inhibitor of 5,10-methylenetetrahydrofolate reductase (MTHFR) and positive modulator of 
cystathionine ^-synthase (CBS), whereas 5-methyltetrahydrofolate (5-CH^-THF) is an 
inhibitory ligand for GNMT. Other abbreviations used: BHMT, betaine homocysteine 
methyltransferase; MS, methionine synthase; THF, tetrahydrofolate. 
FIGURE 2 Induction of hepatic glycine N-methyltransferase (GNMT) by retinoic acid 
(RA) in sham-operated and adrenalectomized (ADX) rats. Sham-operated and ADX male 
Sprague Dawley rats were treated with a daily dose of RA (30 ^mol/kg BW) for 7 d. Liver 
samples were removed and analyzed for GNMT activity and abundance as described under 
"Materials and Methods." Data are expressed as means ± SEM (n=5) and bars denoted with 
different letters are significantly different (p < 0.05). A, GNMT enzyme activity in sham-
operated and ADX rats following administration of RA or corn oil. B, Western blot analysis 
of GNMT abundance in sham-operated and ADX rats following administration of RA or 
corn oil. A polyclonal IgG-purified antibody against rat liver GNMT was used and a 
representative immunoblot is shown with the relative fold induction indicated under each 
lane. 
FIGURE 3 Induction of hepatic glycine N-methyltransferase (GNMT) by retinoic acid 
(RA), dexamethasone (DEX) in sham-operated and adrenalectomized (ADX) rats. Sham-
operated and ADX male Sprague Dawley rats were treated with either a daily dose of RA (30 
pmol/kg BW), DEX (1 mg/kg BW), or both. After 5 d, liver samples were removed and 
GNMT activity was determined as described under "Materials and Methods". Data are 
means ± SEM (n=5) and bars denoted by a different letter are significantly different (p < 
0.05). 
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FIGURE 4 Regulation of hepatic and pancreatic glycine N-methyltransferase (GNMT) 
abundance by retinoic acid (RA) and dexamethasone (DEX) in sham-operated and 
adrenalectomized (ADX) rats. Tissue samples from the same rats as described for Fig. 3 
were used for the determination of GNMT abundance by Western blot analysis as described 
under "Materials and Methods". A, representative immunoblot of hepatic GNMT abundance 
in sham-operated and ADX rats treated with RA, DEX, or both compounds. The relative 
fold-induction is indicated under each lane. B, representative immunoblot of pancreatic 
GNMT abundance in sham-operated rats treated with RA, DEX, or both compounds. All 
blots are representative examples from individual rat tissue samples. 
FIGURE 5 Plasma homocysteine concentrations in sham-operated and adrenalectomized 
(ADX) rats following treatment with retinoic acid (RA), dexamethasone (DEX), or both. 
Plasma samples from the same rats as described for Fig. 3 were obtained for the assessment 
of total homocysteine concentrations by high-performance liquid chromatography as 
described under "Materials and Methods". Data are means ± SEM (n=5) and bars denoted by 
a different letter are significantly different (p < 0.05). 
FIGURE 6 Comparison of retinoic acid (RA) regulation of glycine N-methyltransferase 
(GNMT) abundance in rat hepatoma cells and rat liver. H4IIE rat hepatoma cells (lanes 1-4) 
were treated with 10 ^imol/L RA dissolved in MeiSO (lanes 2 and 4) or an equivalent 
volume ofMe2SO (100 jxL/L final concentration) alone (lanes 1 and J). Following a 72-h 
incubation period, cells were lysed and Western blot analysis was performed as described 
under "Materials and Methods". Male Sprague Dawley rats were administered a single dose 
of RA (30 pmol/kg BW) or corn oil daily for a total of 7 d. Liver samples were removed for 
determination of GNMT abundance by Western blot analysis as described under "Materials 
and Methods". For comparison purposes, 75 ( lanes 1, 2, 5 and 6) and 150 \xg of total protein 
(lanes 3,4,7 and 8) were analyzed for both cell and tissue lysates. 
FIGURE 7 Regulation of glycine N-methyltransferase (GNMT) by retinoic acid (RA) and 
dexamethasone (DEX) in rat hepatoma cells. H4IIE rat hepatoma cells were treated with 
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either DEX (0.1 pmol/L), RA (10 |imol/L), or both. After a 72-h incubation period, cells 
were lysed and GNMT abundance was determined as described under "Materials and 
Methods". The representative immunoblot and the densitometric analysis shown in the bar 
graph were generated from three independent experiments. 
FIGURE 8 Regulation of glycine N-methyltransferase (GNMT) abundance by various 
combinations of retinoic acid (RA), dexamethasone (DEX), dibutyryl-cAMP (BtzcAMP), and 
glucagon in rat hepatoma cells. H4IIE rat hepatoma cells were treated alone or with various 
combinations of DEX, RA, Bt%cAMP, or glucagon. After a 72-h incubation period, cells 
were lysed and GNMT abundance was determined as described under "Materials and 
Methods". A, lane 1, MeaSO-treated control; lane 2, RA (10 (imol/L); lane 3, DEX (0.1 
|xmol/L); lane 4, Bt^cAMP (0.5 mmol/L); lane 5, RA + Bt^cAMP; lane 6, RA + DEX; lane 7, 
DEX + BtacAMP; and lane 8, RA + DEX + Bt^cAMP. B, lane 1, MeaSO-treated control; 
lane 2, RA + DEX; lane 3, glucagon (0.5 jjmol/L); lane 4, Bt^cAMP; and lane 5, rat liver 
(RA-treated) positive control. 
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GENERAL CONCLUSIONS 
GNMT is a key regulatory protein that controls the supply of methyl groups available 
for transmethylation reactions by facilitating the disposal of excess SAM. Therefore, 
inappropriate activation of GNMT may lead to conditions consistent with methyl group 
deficiency. In the work presented in this dissertation, I illustrated for the first time that 
retinoids represent a family of nutritional compounds that have the ability to induce the gene 
expression of hepatic GNMT, which in turn resulted in the increased catabolism of methyl 
groups and compromised transmethylation reactions, namely the methylation of hepatic 
DNA. These findings clearly indicate that GNMT up-regulation has possible implications 
for the development of pathological conditions that are associated with abnormal methyl 
group metabolism, such as cancer, neural tube defects, and heart disease (Salmon and 
Copeland 1954; Clarke et al. 1991; Haynes 2003). 
Enzymatically active GNMT resides primarily in gluconeogenic tissues, such as the 
liver, kidney, and pancreas (Yeo and Wagner 1994), which suggests that GNMT has a role 
during gluconeogenesis. Additionally, GNMT has been shown to be up-regulated during 
conditions associated with gluconeogenesis, a process during which retinoic acid, along with 
hormones such as glucocorticoids and glucagon, are known to increase the gene expression 
of various gluconeogenic enzymes, such as PEPCK, the rate-limiting enzyme of 
gluconeogenesis (Pan et al. 1990; Shin and McGrane 1998). However, to date no retinoic 
acid response elements have been discovered in the promoter region of the GNMT gene, 
indicating RA may require alternative signals to exert its effect on GNMT. Previous studies 
showed that functional adrenal glands were required to alleviate the symptoms of methionine 
toxicity following treatment with retinol (Peng and Evenson 1982), indicating that 
glucocorticoid secretion from the adrenals may play a key role in the catabolism of 
methionine. Hence, we postulated that the effect of retinoids on GNMT expression is 
mediated by an induction of gluconeogenesis due to increased blood concentrations of 
counter-regulatory hormones, namely glucocorticoids secreted from the adrenals. However, 
since my studies showed that GNMT activity and abundance did not differ between ADX 
and sham control rats given DEX and/or RA, I have concluded that, although it is clear that 
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glucocorticoids have a similar ability to that of retinoids to induce enzymatically active 
GNMT, the induction of GNMT by retinoids does not require adrenal function. We believe 
that the discovery of glucocorticoids as hormonal factors that can modulate GNMT 
expression is a significant finding however, because it indicates that, like retinoids, elevated 
levels of glucocorticoids, which are commonplace during uncontrolled diabetes, may perturb 
methyl group metabolism in a fashion similar to that of RA. 
The mechanism by which nutritional and hormonal factors increase GNMT 
expression remains unclear. Because our findings do not suggest a synergistic effect results 
from the co-administration of retinoids and glucocorticoids, but rather an additive effect on 
the induction of active GNMT protein in both animal and cell culture models, we believe it is 
likely that these two families of compounds modulate GNMT by two separate mechanisms. 
This is supported by our work that showed co-administration of RA and DEX at saturating 
concentrations produced an additive effect in increasing GNMT activity and abundance in 
rats. Likewise, GNMT abundance was elevated in H4IIE cells in a similar fashion upon 
direct administration of DEX and RA, which clearly suggests that the effect of these 
compounds on GNMT is mediated at the cellular level. 
Elucidating the mechanism by which nutritional and hormonal factors influence 
GNMT gene expression remains an area of intense research in our laboratory. We have 
recently discovered that the effect of RA and DEX on GNMT was prevented in H4IIE cells 
pre-treated with actinomycin D (Rowling and Schalinske, unpublished observations), a 
potent inhibitor of transcription. This provides evidence that the effect of RA and DEX on 
GNMT may be mediated at the transcriptional level. To expand on these findings, we are 
currently conducting experiments that measure GNMT mRNA levels in rats and cells that 
have been treated with a number of nutritional and hormonal factors, including as RA and 
DEX. However, because RA- and DEX- mediated GNMT protein induction may not be due 
solely to increased transcription, but rather stabilization of GNMT mRNA, increased 
translation and/or GNMT protein stabilization, we are conducting sets of experiments that 
measure the synthesis and degradation rates of GNMT mRNA and GNMT protein. Taken 
together, we expect that these experiments will assist us in pinpointing the cellular 
mechanism that is being utilized to increase the expression of GNMT. 
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We are also in the process of planning and conducting experiments that utilize our 
diabetic rat and cell culture models to explore the possible mechanistic role of insulin in the 
prevention of abnormal methyl group metabolism as well as to discover interactions between 
diabetes and retinoid compounds as they relate to increased GNMT expression and 
alterations of other aspects of methyl group, folate, and homocysteine metabolism. Although 
we are still at the early stages of this research area, we have recently discovered that 
treatment of H4IIE hepatoma and AR42J pancreatic tumor cells with insulin prevented 
induction of GNMT protein abundance following RA and DEX treatment (Rowling and 
Schalinske, unpublished observations). 
I expect that the research presented in this dissertation, as well as future research in 
Dr. Schalinske's laboratory, will help provide a basis for (i) establishing future dietary 
recommendations to prevent abnormal methyl group metabolism in diabetics and those using 
therapeutic retinoids, (ii) identifying individuals at risk for pathological conditions associated 
with abnormal methyl group metabolism, and (iii) evaluating interactions between increased 
GNMT expression and common inborn errors of methyl group metabolism. 
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